CN110684015A - 靶向alk的protac及其应用 - Google Patents

靶向alk的protac及其应用 Download PDF

Info

Publication number
CN110684015A
CN110684015A CN201810738298.4A CN201810738298A CN110684015A CN 110684015 A CN110684015 A CN 110684015A CN 201810738298 A CN201810738298 A CN 201810738298A CN 110684015 A CN110684015 A CN 110684015A
Authority
CN
China
Prior art keywords
nmr
cdcl
synthesis
dart
hrms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810738298.4A
Other languages
English (en)
Inventor
李锐
魏于全
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan University
Original Assignee
Sichuan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan University filed Critical Sichuan University
Priority to CN201810738298.4A priority Critical patent/CN110684015A/zh
Publication of CN110684015A publication Critical patent/CN110684015A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1003—Carbocyclic compounds
    • C09K2211/1007—Non-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及靶向ALK的PROTAC及其应用，属于抗肿瘤药物技术领域。本发明解决的技术问题是提供一种靶向ALK的PROTAC分子。该PROTAC分子，其结构式如式Ⅰ所示。本发明选用CRBN的配体泊马度胺及其衍生物为E3连接酶配体，通过不同种类、不同链长的linker将ALK抑制剂LDK378与E3连接酶偶联，成功制备得到了靶向ALK的PROTAC分子，能有效靶向于目标蛋白，并降低细胞中ALK的含量，同时具有较好的体内体外抗肿瘤活性，对正常细胞毒性较低，符合高效低毒的特征。

Description

靶向ALK的PROTAC及其应用
技术领域
本发明涉及靶向ALK的PROTAC及其应用，属于抗肿瘤药物技术领域。
背景技术
蛋白水解靶向嵌合体(proteolysis-targeting chimeras,PROTAC)是具有两个异功能的配体通过linker连接的化合物：一个配体靶向于目的蛋白(POI)，而另一个配体特异性地募集E3连接酶。当PROTAC结合E3连接酶和目的蛋白时形成了三元复合物，通过劫持E3连接酶，PROTAC使POI呈现出有利的空间位置以促进其泛素化，从而选择性地降低靶蛋白的水平。这种方法的优点是PROTAC可以催化样的多轮降解靶蛋白，这是PROTAC分子与小分子抑制剂最大的不同。
间变性淋巴瘤激酶(Anaplastic Lymphoma Kinase，ALK)是一种受体酪氨酸激酶，与血液、间质和实体三大类型肿瘤相关。约3-7％的非小细胞肺癌(NSCLC)患者体内肿瘤染色体EML4基因外显子与ALK基因外显子融合，形成EML4-ALK融合酪氨酸激酶，EML4-ALK融合变异体具有高度的致癌性，且ALK在多种肿瘤细胞中高表达。因此，ALK成为一个极具吸引力的癌症治疗靶点。
LDK378，通用名：色瑞替尼，商品名：Zykadia，是目前已经上市的ALK抑制剂，适用于有间变性淋巴瘤激酶(ALK)-阳性转移对克唑替尼进展或不能耐受的非小细胞肺癌(NSCLC)患者的治疗。其主要成分的化学结构式为：
Figure BDA0001722582780000011
对LDK378进行结构改造，将LDK378与E3连接酶配体结合形成PROTAC，可以催化样的多轮降解靶蛋白，选择性地降低靶蛋白的水平。
专利CN104736569A公开了通过E3泛素连接酶增强靶蛋白及其他多肽降解的化合物和方法，主要是采用VHL配体作为E3连接酶配体，将靶向的蛋白质/多肽引至E3连接酶，以进行泛素化和随后的蛋白酶体降解。但是，发明人研究发现，LDK378与VHL配体连接形成的PROTAC分子与阳性药物LDK378相比，对ALK的激酶活性急剧下降，且抗肿瘤活性下降。
发明内容
针对以上缺陷，本发明解决的技术问题是提供一种靶向ALK的PROTAC分子。
本发明的靶向ALK的PROTAC分子，其结构式如式Ⅰ所示：
Figure BDA0001722582780000021
其中，L为连接体基团。
本发明还提供本发明所述的化合物在制备抗肿瘤药物中的应用。
本发明的化合物，可用于制备抗肿瘤药物。尤其适用于制备治疗肺癌或者宫颈癌的药物。
本发明还提供了药物组合物，它包含治疗有效量的本发明所述的化合物以及至少一种可药用的载体。
本发明还提供本发明所述的化合物在制备荧光示踪剂或肿瘤标志物中的应用。
本发明化合物，具有荧光，可以制备成荧光示踪剂或肿瘤标志物，可用于追踪化合物分子在细胞内或体内的分布。
与现有技术相比，本发明具有如下有益效果：
本发明选用CRBN的配体泊马度胺及其衍生物为E3连接酶配体，通过不同种类、不同链长的linker将ALK抑制剂LDK378与E3连接酶偶联，成功制备得到了靶向ALK的PROTAC分子，能有效靶向于目标蛋白，并降低细胞中ALK的含量，同时具有较好的体内体外抗肿瘤活性，对正常细胞毒性较低，符合高效低毒的特征。此外，该分子具有荧光，可以用于追踪化合物分子在细胞内或体内的分布。
附图说明
图1为化合物B3处理过H3122细胞12h后ALK及相关蛋白含量变化图。
图2为化合物B3处理的H3122细胞的PI/Annexin V双染实验。
图3为化合物B3的波长-吸收曲线。
图4为化合物B3在420nm激发光下的不同波长发射荧光强度。
图5为化合物B3分子在细胞内的分布图。
图6为不同细胞加入化合物B3后细胞内的荧光强度图。
图7为肿瘤体积随给药时间的变体曲线。
图8为裸鼠体重随给药时间的变体曲线。
具体实施方式
本发明的靶向ALK的PROTAC分子，其结构式如式Ⅰ所示：
Figure BDA0001722582780000031
其中，L为连接体基团。
优选的，L为其中，*端连接色瑞替尼哌啶环中的N，Z为-CH2-、-NH-、-O-、-S-、
Figure BDA0001722582780000033
Figure BDA0001722582780000034
Figure BDA0001722582780000035
Z1为-CH2-、-NH-、-O-、-S-、
Figure BDA0001722582780000036
Figure BDA0001722582780000037
Z2为-CH2-、-NH-、-O-或-S-，m0为0～15中任一整数，m为0～15中任一整数，m1为0～8中任一整数，m2为0～8中任一整数，m3为0～8中任一整数，m4为0～15中任一整数，m5为0～15中任一整数；n为1～3中任一整数；M为H或1～8的饱和烷烃或环烷烃。
优选的，Z为Z1为-NH-、
Figure BDA0001722582780000039
Figure BDA0001722582780000041
Z2为-CH2-或-O-。
优选的，m0为1或2。
更优选的，Z为
优选的，Z1为-NH-、
Figure BDA0001722582780000043
作为优选方案，Z2为-O-，m1为1，m2为1。
优选的，其结构式如B2、B3、C2、D1或G1所示：
本发明的化合物，可用于制备抗肿瘤药物。尤其适用于制备治疗肺癌或者宫颈癌的药物。
本发明的化合物可以单独使用，也可与可药用的载体或赋形剂一起以药物组合物的形式使用，当以药物组合物的形式使用时，通常将治疗有效量的本发明化合物以及一种或多种可药用载体或稀释剂结合制成适当的施用形式或剂量形式。因此，本发明还提供了药物组合物，它包含治疗有效量的本发明所述的化合物以及至少一种可药用的载体。
本发明化合物的药用组合物，可以以下方面的任意方式施与：口服、喷雾吸入、直肠给药、鼻腔给药、阴道给药、局部给药、非肠道给药如皮下、静脉、肌内、腹膜内、销内、心室内、胸骨内或颅内注射或输入，或借助一种外植的储器用药，其中优选口服、肌注、腹膜内或静脉内用药方式。
本发明化合物，具有荧光，可以制备成荧光示踪剂或肿瘤标志物，可用于追踪化合物分子在细胞内或体内的分布。
下面结合实施例对本发明的具体实施方式做进一步的描述，并不因此将本发明限制在所述的实施例范围之中。
实施例1
1、L系列分子的合成
Figure BDA0001722582780000051
(i)乙二酰氯,DMF,rf,2h；(ii)三乙胺,DCM,rt,15h(iii)EDCI,Hobt,DCM,rt,12h
中间体P4的合成
Figure BDA0001722582780000052
将原料丁二酸(118mg,0.1mmol)加入SOCL2中，加入2滴DMF，加热，回流反应2h。将反应液常温减压干燥得产物1.
将产物1溶于无水DCM中，加入pomalidomide和Triethylamine，在常温下反应15h。反应完成后，用水淬灭反应，用EA萃取三次，有机层用饱和食盐水洗两次，无水硫酸钠干燥，浓缩，用柱层析分离得中间体P4.
1H NMR(400MHz,DMSO)δ＝8.47(d,J＝8.1,1H),7.82(dd,J＝8.4,7.4,1H),7.60(d,J＝6.9,1H),5.14(dd,J＝12.8,5.4,1H),2.91(ddd,J＝19.1,12.4,5.4,2H),2.61(dt,J＝15.3,5.5,4H),2.49–2.45(m,2H).HRMS(DART-TOF)calculated for C17H16N3O7[M+H]+m/z374.0988,found374.0981.
目标产物L4P的合成：
将中间体P4溶于无水DCM中，加入EDCI和Hobt,最后加入LDK378，常温反应12h。反应完成后，加入水，用EA萃取三次，有机层用饱和食盐水洗两次，用无水硫酸钠干燥，浓缩，用柱层析分离得目标产物，产率约为65％.
1H NMR(400MHz,CDCl3)δ＝9.64(s,1H),8.82(d,J＝8.4,1H),8.57(d,J＝8.2,1H),8.20(d,J＝4.8,1H),8.15(s,1H),7.98(d,J＝5.3,1H),7.96–7.92(m,1H),7.73–7.67(m,1H),7.65–7.59(m,1H),7.57–7.51(m,1H),7.32–7.27(m,1H),6.70(s,1H),4.96(dt,J＝10.8,5.5,1H),4.80(d,J＝12.8,1H),4.56(dp,J＝12.1,6.0,1H),3.35–3.12(m,2H),3.02–2.64(m,9H),2.18(s,3H),1.91–1.49(m,8H),1.42–1.27(m,13H).13C NMR(101MHz,CDCl3)δ＝171.95,170.64,169.42,169.38,167.79,166.75,155.48,137.85,136.26,134.62,131.32,131.19,126.86,125.33,125.05,123.69,123.29,118.38,115.47,110.91,71.71,55.54,49.28,46.20,42.88,38.32,32.79,32.29,31.40,22.67,22.27,18.96,15.37.HRMS(DART-TOF)calculated for C45H50ClN8O9S[M+H]+m/z 913.3110,found 913.3119.
中间体P6的合成：
Figure BDA0001722582780000062
中间体P6的合成步骤参照P4，但将原料换为己二酸，产率约为61％
1H NMR(400MHz,DMSO)δ＝11.16(s,1H),9.72(s,1H),8.46(d,J＝8.4,1H),7.96–7.77(m,1H),7.62(d,J＝7.3,1H),5.15(dd,J＝12.8,5.4,1H),2.90(ddd,J＝16.7,13.8,5.3,1H),2.61(dd,J＝14.6,3.9,1H),2.29–2.15(m,4H),2.12–2.01(m,1H),1.71–1.52(m,3H).13C NMR(101MHz,DMSO)δ＝174.98,173.26,172.34,170.29,168.09,167.15,136.97,136.56,131.95,126.86,118.80,117.55,49.36,36.64,34.12,31.40,24.79,24.63,24.56,22.45.HRMS(DART-TOF)calculated for C19H20N3O7[M+H]+m/z 402.1301,found 402.1313.
目标产物L6P的合成
Figure BDA0001722582780000071
目标产物L6P的合成步骤参照L4P，但将原料换为P6，产率约为48％。
1H NMR(400MHz,CDCl3)δ＝9.55(s,1H),9.43(s,1H),8.82(d,J＝8.4,1H),8.58(d,J＝8.2,1H),8.44(s,1H),8.16(s,1H),8.00(s,1H),7.93(dd,J＝8.0,1.5,1H),7.75–7.69(m,1H),7.62(dd,J＝11.0,3.9,1H),7.58–7.52(m,1H),7.31–7.27(m,1H),6.69(s,1H),4.96(dd,J＝11.7,4.8,1H),4.83(d,J＝13.1,1H),4.63–4.48(m,1H),3.22(ddd,J＝43.8,19.1,9.3,2H),2.99–2.59(m,5H),2.49(dt,J＝14.1,6.8,4H),2.18(s,4H),1.90–1.48(m,10H),1.41–1.28(m,13H).13C NMR(101MHz,CDCl3)δ＝172.00,170.79,170.74,169.16,167.89,166.68,155.42,144.93,138.42,137.82,136.44,134.62,131.30,131.13,127.76,126.87,125.29,124.97,123.66,123.21,121.00,118.49,115.35,110.91,71.68,55.51,49.30,46.47,42.63,38.38,37.69,33.45,32.95,32.30,31.39,24.96,24.72,22.68,22.27,22.18,18.96,15.37.HRMS(DART-TOF)calculated for C47H53ClN8O9SNa[M+Na]+m/z963.3242,found 963.3241.
中间体P7的合成：
Figure BDA0001722582780000072
中间体P7的合成步骤参照P4，但将原料换为庚二酸，产率约为59％
1H NMR(400MHz,DMSO)δ＝9.72(s,1H),8.47(d,J＝8.4,1H),7.91–7.76(m,1H),7.61(d,J＝7.2,1H),5.15(dd,J＝12.8,5.4,1H),2.59(ddd,J＝25.5,16.5,13.1,2H),2.19(dt,J＝14.7,7.4,8H),1.75–1.59(m,2H),1.39–1.13(m,6H).13C NMR(101MHz,DMSO)δ＝175.04,173.25,172.44,170.28,168.12,167.15,137.00,136.56,131.94,126.81,118.77,117.50,49.36,40.58,40.37,40.16,39.96,39.75,39.54,39.33,36.82,34.23,31.40,28.65,28.56,25.01,24.81,22.44,21.81.HRMS(DART-TOF)calculated for C20H22N3O7[M+H]+m/z 416.1458,found 416.1447.
目标产物L7P的合成
Figure BDA0001722582780000081
目标产物L7P的合成步骤参照L4P，但将原料换为P7，产率约为38％。
1H NMR(400MHz,CDCl3)δ＝9.43(s,1H),8.83(d,J＝8.5,1H),8.57(d,J＝8.3,1H),8.14(s,1H),7.94(dd,J＝8.0,1.4,1H),7.78–7.68(m,1H),7.61(t,J＝7.8,1H),7.56–7.52(m,1H),7.29(d,J＝6.6,1H),6.69(s,1H),4.95(dd,J＝12.2,5.3,1H),4.83(d,J＝12.9,1H),4.55(dt,J＝12.2,6.1,1H),4.00(d,J＝13.4,1H),3.22(ddd,J＝45.5,19.0,9.7,3H),3.00–2.58(m,5H),2.49(t,J＝7.5,2H),2.44–2.36(m,2H),2.17(d,J＝6.3,4H),1.67(dddd,J＝36.1,23.0,14.9,7.6,15H),1.33(dt,J＝30.8,14.6,13H).HRMS(DART-TOF)calculated for C48H55ClN8O9SNa[M+Na]+m/z 977.3399,found977.3368.
中间体P8的合成：
Figure BDA0001722582780000082
中间体P8的合成步骤参照P4，但将原料换为辛二酸，产率约为61％
1H NMR(400MHz,DMSO)δ＝9.69(s,1H),8.47(d,J＝8.3,1H),7.87–7.79(m,1H),7.61(d,J＝7.3,1H),5.14(dd,J＝12.8,5.4,1H),2.90(ddd,J＝16.7,13.7,5.2,1H),2.67–2.51(m,2H),2.46(t,J＝7.4,2H),2.20–2.01(m,6H),1.69–1.36(m,6H).13C NMR(101MHz,DMSO)δ＝175.10,173.22,172.48,170.25,168.15,167.15,137.03,136.56,131.94,126.79,118.76,117.50,49.39,40.64,40.43,40.22,40.01,39.80,39.59,39.38,36.94,34.35,31.41,28.76,28.71,25.13,24.94.HRMS(DART-TOF)calculated for C20H22N3O7[M+H]+m/z 416.1458,found 416.1447.
中间体P9的合成：
Figure BDA0001722582780000091
中间体P9的合成步骤参照P4，但将原料换为壬二酸，产率约为58％
1H NMR(400MHz,DMSO)δ＝8.47(d,J＝8.4,1H),7.91–7.78(m,1H),7.61(d,J＝7.1,1H),5.15(dd,J＝12.8,5.4,1H),2.90(ddd,J＝16.7,13.8,5.2,1H),2.18(t,J＝6.9,8H),1.55–1.42(m,10H).13C NMR(101MHz,DMSO)δ＝175.02,173.25,172.56,172.50,170.28,168.15,167.15,137.02,136.56,131.93,126.76,118.75,117.45,49.36,40.57,40.36,40.16,39.95,39.74,39.53,39.32,36.94,34.16,31.40,28.93,28.89,28.84,28.73,25.20,24.94,24.83,22.44,21.61.HRMS(DART-TOF)calculated for C22H26N3O7[M+H]+m/z 444.1771,found 444.1762.
目标产物L9P的合成
目标产物L9P的合成步骤参照L4P，但将原料换为P9，产率约为45％。
1H NMR(400MHz,CDCl3)δ＝9.45(s,1H),8.83(d,J＝8.5,1H),8.56(d,J＝8.4,1H),8.13(s,1H),7.96–7.90(m,1H),7.76–7.68(m,1H),7.61(t,J＝7.9,1H),7.55(d,J＝7.0,1H),7.29(d,J＝7.7,1H),6.69(s,1H),4.95(dd,J＝12.4,5.4,1H),4.84(d,J＝13.8,1H),3.27(dd,J＝13.7,6.8,1H),3.19–3.10(m,1H),2.91(t,J＝15.1,2H),2.84–2.73(m,2H),2.70–2.58(m,1H),2.47(t,J＝6.5,1H),2.42–2.34(m,2H),2.18(s,3H),1.76(dd,J＝58.1,42.8,18H),1.36(dt,J＝15.7,7.2,11H).HRMS(DART-TOF)calculated for C50H59ClN8O9SNa[M+Na]+m/z 1005.3112,found1005.3720.
目标产物L10P的合成
Figure BDA0001722582780000093
目标产物L10P的合成步骤参照L4P，但将原料换为P10，产率约为31％。
1H NMR(400MHz,CDCl3)δ＝9.45(s,1H),8.81(t,J＝9.4,1H),8.68(s,1H),8.56(d,J＝8.4,1H),8.13(s,1H),7.94(dd,J＝8.0,1.3,2H),7.74–7.68(m,1H),7.60(t,J＝7.4,1H),7.56–7.51(m,1H),7.28(t,J＝5.1,1H),6.68(s,1H),4.96(dd,J＝12.0,5.5,1H),4.84(d,J＝13.0,1H),4.52(t,J＝10.8,1H),4.01(dd,J＝15.6,9.0,1H),3.25(dt,J＝13.7,6.8,1H),3.14(t,J＝12.3,1H),2.92(dd,J＝24.8,9.5,3H),2.84–2.72(m,2H),2.63(t,J＝12.0,2H),2.42(dt,J＝14.9,6.9,5H),2.18(s,4H),1.86–1.49(m,16H),1.44–1.29(m,22H).13C NMR(101MHz,CDCl3)δ＝172.39,172.03,171.73,170.79,169.21,167.89,166.72,137.26,136.43,134.63,131.34,131.15,126.81,125.26,123.71,118.41,115.34,77.34,77.02,77.02,76.70,71.68,55.59,49.32,42.58,38.41,38.01,33.50,32.43,31.42,29.26,29.12,28.98,25.27,22.18,18.95,15.37.HRMS(DART-TOF)calculated forC51H61ClN8O9SNa[M+Na]+m/z 1019.3868,found 1019.3871.
中间体P11的合成：
Figure BDA0001722582780000101
中间体P11的合成步骤参照P4，但将原料换为十一烷二酸，产率约为52％
1H NMR(400MHz,DMSO)δ＝9.70(s,1H),8.47(d,J＝8.3,1H),7.91–7.77(m,1H),7.61(d,J＝6.8,1H),5.14(dd,J＝12.8,5.4,1H),2.90(ddd,J＝16.5,13.6,5.2,1H),2.65–2.53(m,1H),2.45(t,J＝7.4,2H),2.16–2.02(m,6H),1.61(dd,J＝14.1,7.0,2H),1.52–1.40(m,5H),1.37–1.24(m,10H).13C NMR(101MHz,DMSO)δ＝175.53,173.22,172.51,170.25,168.15,167.15,137.05,136.56,131.94,126.78,118.74,117.48,49.39,37.00,35.19,35.07,29.24,29.18,29.07,28.96,25.31.HRMS(DART-TOF)calculated forC24H30N3O7[M+H]+m/z 472.2084,found 472.2065.
目标产物L11P的合成
Figure BDA0001722582780000102
目标产物L11P的合成步骤参照L4P，但将原料换为P11，产率约为29％。
1H NMR(400MHz,CDCl3)δ＝9.44(s,1H),8.83(d,J＝8.4,1H),8.56(d,J＝8.3,1H),8.14(s,1H),7.94–7.91(m,1H),7.74–7.68(m,1H),7.61(dd,J＝11.4,4.4,1H),7.54(dd,J＝7.3,0.6,1H),7.28(d,J＝8.4,1H),6.68(s,1H),4.96(dd,J＝12.2,5.3,1H),4.84(d,J＝13.0,1H),4.59–4.48(m,1H),4.07–3.90(m,2H),3.26(dq,J＝13.7,6.9,1H),3.16(dd,J＝24.5,11.9,1H),2.98–2.73(m,4H),2.68–2.57(m,1H),2.46(t,J＝7.4,2H),2.43–2.36(m,2H),2.17(s,3H),1.89–1.60(m,10H),1.38–1.30(m,21H).13C NMR(101MHz,CDCl3)δ＝172.42,171.73,170.82,169.21,167.96,166.73,155.54,137.90,136.43,134.63,131.33,131.14,125.27,123.70,118.40,115.32,110.90,71.65,55.57,49.33,46.58,42.59,38.40,38.03,33.47,31.93,31.44,29.70,29.56,29.44,29.25,29.04,25.43,25.28,23.92,22.69,22.16,18.94,15.36,14.11.HRMS(DART-TOF)calculated forC52H63ClN8O9SNa[M+Na]+m/z 1033.4025,found 1033.4023.
中间体P12的合成：
中间体P12的合成步骤参照P4，但将原料换为十二烷二酸，产率约为46％
1H NMR(400MHz,DMSO)δ＝9.68(s,1H),8.47(d,J＝8.3,1H),7.88–7.78(m,1H),7.61(d,J＝7.3,1H),5.14(dd,J＝12.7,5.4,1H),2.45(t,J＝7.4,2H),2.16(t,J＝7.3,9H),1.61(dd,J＝14.3,7.0,2H),1.55–1.39(m,9H),1.30(s,4H).HRMS(DART-TOF)calculated for C25H32N3O7[M+H]+m/z 486.2240,found 486.2213.
目标产物L12P的合成
Figure BDA0001722582780000112
目标产物L12P的合成步骤参照L4P，但将原料换为P12，产率约为31％。
1H NMR(400MHz,CDCl3)δ＝8.56(d,J＝8.0,1H),8.16(s,1H),8.03(s,1H),8.03(s,1H),7.94(d,J＝7.9,1H),7.78(d,J＝8.1,1H),7.67(d,J＝8.3,1H),7.65–7.59(m,1H),7.56(s,1H),7.39–7.28(m,3H),6.76(s,1H),4.58–4.48(m,1H),3.82(d,J＝13.2,2H),3.25(dd,J＝13.9,6.8,3H),2.34(s,12H),2.16(s,3H),1.97(d,J＝15.2,2H),1.68(s,7H),1.30(dd,J＝14.5,8.4,13H),1.26(s,12H).HRMS(DART-TOF)calculated for C53H65ClN8O9SNa[M+Na]+m/z 1047.4181,found1047.4181.
2、A系列PROTAC分子合成：
Figure BDA0001722582780000121
中间体1的合成：
Figure BDA0001722582780000122
以LDK378为原料(330mg,0.6mmol)，溶于50mL甲醇，加入丙烯酸甲酯(78mg,0.9mmol),三乙胺(240mg,2.4mmol)，常温搅拌8h，TLC检测反应进度。处理方法：先减压蒸馏除去甲醇，加入150mL乙酸乙酯，用水反洗有机溶液三次，用无水硫酸钠除水后减压浓缩，用PE/EA分离体系进行柱层析，得到白色固体，产率约为90％。
1H NMR(400MHz,CDCl3)δ＝9.49(s,1H),8.58(d,J＝8.4,1H),8.15(s,1H),7.99(s,1H),7.93(d,J＝8.0,1H),7.62(t,J＝7.9,1H),7.53(s,1H),7.24(d,J＝7.7,1H),6.80(s,1H),4.53(dt,J＝12.1,6.0,1H),3.71(s,3H),3.32–3.21(m,1H),3.06(d,J＝9.6,2H),2.77(d,J＝6.7,2H),2.72–2.52(m,3H),2.15(s,4H),1.76(s,4H),1.34(dd,J＝15.0,6.5,12H).13C NMR(101MHz,CDCl3)δ＝157.52,155.39,155.33,144.72,138.52,134.65,131.25,127.46,126.87,124.91,123.71,123.09,120.63,110.82,105.72,71.43,55.45,54.30,53.90,51.71,37.94,32.77,22.27,18.93,15.37.HRMS(DART-TOF)calculated forC32H43ClN5O5S[M+H]+m/z 644.2673,found 644.2673.
中间体2的合成：
Figure BDA0001722582780000131
将中间体1(320mg，0.5mmol)溶于50mL甲醇和水1：1的混合液，加入氢氧化钠(200mg，5mmol),60℃下搅拌10h，反应液由澄清变浑浊，TLC监测反应。反应处理：先减压旋蒸除去甲醇，用稀盐酸调节水层pH至2。然后用EA萃取3次，取油层用饱和食盐水反洗1次，用无水硫酸钠干燥后减压浓缩，即得产物，白色粉末，产率约为95％。
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.58(d,J＝8.4,1H),8.16(d,J＝1.2,1H),8.03(d,J＝3.2,1H),7.93(d,J＝7.9,1H),7.62(dd,J＝11.3,4.4,1H),7.58–7.51(m,1H),7.27(d,J＝6.5,1H),6.75(d,J＝37.6,1H),4.56(dt,J＝11.1,5.6,1H),3.51–3.14(m,3H),2.81(ddd,J＝47.2,24.3,12.3,3H),2.17(d,J＝8.1,3H),1.34(dd,J＝14.8,6.5,13H).HRMS(DART-TOF)calculated for C31H41ClN5O5S[M+H]+m/z 630.2517,found 630.2508.
中间体3的合成：
称取LDK378(560mg，1mmol),溶于50mL乙腈中，加入溴乙酸叔丁酯(195mg，1mmol),碳酸钾(414mg，3mmol),回流5h，用TLC监测反应。反应完全后加入30mL水淬灭反应，用100mL的EA萃取3次，后用水反洗3次。有机层用无水硫酸钠干燥，减压浓缩，用PE/EA作为流动相进行柱层析分离。得黄色固体，产率约为76％。
1H NMR(400MHz,CDCl3)δ＝9.49(s,1H),8.58(d,J＝8.3,1H),8.14(s,1H),7.97(d,J＝12.7,1H),7.92(d,J＝7.8,1H),7.62(t,J＝7.7,1H),7.54(s,1H),7.26(dd,J＝13.1,5.4,1H),6.82(s,1H),4.51(dq,J＝11.9,6.0,1H),3.34–3.22(m,1H),3.18(s,2H),3.09(d,J＝10.9,2H),2.68(dd,J＝15.9,7.8,1H),2.32(t,J＝10.8,2H),2.16(s,3H),1.82(dt,J＝34.1,11.0,4H),1.49(s,10H),1.34(dd,J＝17.5,6.4,13H).HRMS(DART-TOF)calculatedfor C34H47ClN5O5S[M+H]+m/z 672.2986,found 672.2975.
中间体4的合成：
Figure BDA0001722582780000141
将中间体3溶于20mL三氟乙酸中，常温搅拌5h。反应完全后，在反应液中加入30mLDCM，减压浓缩，最终得白色粉末，产率约为90％。
1H NMR(400MHz,MeOD)δ＝8.29(d,J＝7.9,1H),8.23(s,1H),7.99(d,J＝7.9,1H),7.70(t,J＝7.7,1H),7.51(t,J＝7.6,1H),7.40(s,1H),6.92(s,1H),4.72–4.59(m,1H),4.13(s,2H),3.82(t,J＝18.3,2H),3.35(s,4H),3.13(t,J＝11.7,1H),2.18(d,J＝12.2,3H),2.13–1.92(m,4H),1.37–1.16(m,13H).HRMS(DART-TOF)calculated for C30H39ClN5O5S[M+H]+m/z 616.2360,found616.2347.
中间体A1-M的合成：
Figure BDA0001722582780000142
在20mLNMP中，加入3-氟-N-(2,6-二氧代-3-哌啶基)邻苯二甲酰亚胺(165mg,0.6mmol)N-叔丁氧羰基-1,4-丁二胺(113mg，0.6mmol)，DIPEA(129mg,1mmol),90℃下反应10h，TLC监测反应。反应完成后，在反应液中加入150mLEA混匀后，首先用10％柠檬酸溶液洗2次，每次20mL，后用饱和NaHCO3溶液洗2次，每次20mL，最后用饱和食盐水洗2次后用无水硫酸钠干燥，减压浓缩后用PE/EA分离体系进行柱层析分离。产物为黄色固体，产率约为65％。
1H NMR(400MHz,CDCl3)δ＝8.27(d,J＝30.0,1H),7.42(dd,J＝8.5,7.1,1H),7.02(d,J＝7.0,1H),6.82(d,J＝8.5,1H),4.90–4.79(m,1H),3.23(t,J＝6.9,2H),3.10(t,J＝6.1,2H),2.87–2.63(m,4H),2.12–2.02(m,1H),1.67–1.49(m,4H),1.40(d,J＝19.8,8H).HRMS(DART-TOF)calculated for C22H28N4O6[M+H]+m/z 444.2009,found 444.2001.
中间体A2-M的合成：
该中间体的制备方法同A1-M，原料为N-叔丁氧羰基-1,6-己二胺。产率为63％1HNMR(400MHz,CDCl3)δ＝8.30(s,1H),7.42(dd,J＝8.3,7.3,1H),7.01(d,J＝7.1,1H),6.80(d,J＝8.6,1H),4.85(dd,J＝12.0,5.4,1H),4.50(s,1H),3.19(t,J＝7.0,2H),3.04(t,J＝6.9,2H),2.89–2.55(m,4H),2.06(dt,J＝6.7,3.0,1H),1.65–1.54(m,2H),1.48–1.24(m,15H).HRMS(DART-TOF)calculated for C24H33N4O6[M+H]+m/z 473.2400,found 473.2391.
中间体A3-M的合成：
Figure BDA0001722582780000152
A3-M该中间体的制备方法同上，原料为N-叔丁氧羰基-1,8-辛二胺。产率为61％。
1H NMR(400MHz,CDCl3)δ＝8.30(s,1H),7.49(dd,J＝8.4,7.3,1H),7.08(d,J＝7.1,1H),6.88(d,J＝8.5,1H),4.97–4.87(m,1H),3.26(t,J＝6.9,2H),3.10(s,2H),2.98–2.66(m,4H),2.15(ddd,J＝13.0,10.0,6.3,1H),1.70–1.62(m,2H),1.52–1.29(m,20H).HRMS(DART-TOF)calculated for C26H36N4O6Na[M+Na]+m/z 523.2533,found 523.2512.
目标产物A1的合成：
Figure BDA0001722582780000153
将A1-M(90mg,0.2mmol)溶于5mL三氟乙酸中，常温搅拌5h。停止反应，在反应液中加入10mLDCM并减压浓缩，得棕色油状物。在该油状物中加入10mLDMF溶解，加入中间体2(63mg，0.1mmol)，HATU(45.6mg，0.12mmol),DIPEA(38.7mg，0.3mmol)。常温反应15h，TLC监测反应进度。反应完成后用30mL水淬灭反应，用EA萃取水层4次，合并有机层，用饱和食盐水反洗2次，用无水硫酸钠干燥，减压浓缩，用DCM/MeOH分离体系进行柱层析分离。产物为黄色粉末，产率约40％.
1H NMR(400MHz,CDCl3)δ＝9.45(s,1H),8.51(d,J＝8.3,1H),8.09(s,1H),7.94(s,1H),7.90–7.78(m,1H),7.53(dd,J＝18.5,11.2,3H),7.41(dd,J＝15.8,8.3,1H),7.21–7.10(m,3H),7.00(d,J＝7.1,1H),6.81(d,J＝8.5,1H),6.70(s,1H),6.15(t,J＝5.4,1H),4.94–4.71(m,1H),4.47(dt,J＝11.9,5.9,1H),3.39–3.05(m,8H),2.96–2.29(m,12H),2.08(s,3H),1.84–1.53(m,10H),1.37–1.22(m,13H).13C NMR(101MHz,CDCl3)δ＝171.83,171.20,169.59,168.67,167.55,157.42,155.37,146.87,144.80,138.48,136.23,134.62,132.48,131.30,128.11,127.17,124.92,123.59,123.16,120.82,116.72,111.63,111.06,110.06,105.96,71.88,60.40,55.49,53.86,48.91,42.16,31.71,26.93,26.59,22.23,15.37.HRMS(DART-TOF)calculated for C48H59ClN9O8S[M+H]+m/z 956.3896,found956.3958.
目标产物A2的合成：
Figure BDA0001722582780000161
称取原料A2-M(240mg，0.5mmol)，其它原料和操作方法同目标产物A1。得目标产物为黄色粉末，产率约为35％。
1H NMR(400MHz,CDCl3)δ＝9.46(s,1H),8.51(d,J＝8.3,1H),8.09(d,J＝6.0,1H),7.89(s,1H),7.85(dd,J＝8.0,1.5,1H),7.79(s,1H),7.62(s,1H),7.56–7.49(m,1H),7.43–7.36(m,1H),7.16(d,J＝7.9,1H),7.00(d,J＝7.1,1H),6.78(d,J＝8.5,1H),6.68(s,1H),6.24–6.08(m,1H),4.83(dd,J＝12.3,5.3,1H),4.53–4.37(m,1H),3.29–3.07(m,8H),2.86–2.58(m,8H),2.42(t,J＝6.3,2H),2.19(t,J＝11.4,3H),2.13–2.01(m,5H),1.59(dt,J＝13.9,6.8,3H),1.23(t,J＝9.2,14H).13C NMR(101MHz,CDCl3)δ＝171.98,171.40,169.60,168.91,167.67,157.47,155.38,155.19,146.92,144.97,138.48,136.12,134.62,132.54,131.27,127.82,126.98,124.87,123.61,123.10,121.15,116.57,111.41,110.96,109.98,105.80,71.59,60.40,55.48,54.14,53.81,48.98,42.50,39.12,37.58,32.38,31.93,31.52,29.69,29.44,29.06,26.81,26.67,22.80,22.69,22.12,18.90,15.36,14.20,14.12.HRMS(DART-TOF)calculated for C50H63ClN9O8S[M+H]+m/z 984.4209,found984.4210.
目标产物A3的合成：
Figure BDA0001722582780000171
称取原料A3-M(250mg，0.5mmol)，其它原料和操作方法同目标产物A1。得目标产物为黄色粉末，产率约为41％。
1H NMR(400MHz,CDCl3)δ＝9.53(s,1H),8.58(d,J＝8.3,1H),8.20(s,1H),7.95(s,1H),7.92(dd,J＝8.0,1.4,1H),7.76(s,1H),7.63–7.55(m,1H),7.51–7.44(m,1H),7.27–7.21(m,2H),7.07(d,J＝7.1,1H),6.86(d,J＝8.6,1H),6.73(s,1H),4.91(dd,J＝12.2,5.3,1H),4.58–4.45(m,1H),3.36–3.22(m,5H),3.15(d,J＝11.3,2H),2.95–2.64(m,7H),2.46(t,J＝6.1,2H),2.27–2.09(m,6H),1.90–1.56(m,8H),1.40–1.29(m,19H).13C NMR(101MHz,CDCl3)δ＝172.17,171.49,169.57,169.01,167.72,157.47,155.40,155.09,146.96,145.07,138.47,137.17,136.05,134.63,132.57,131.25,127.68,126.83,124.87,123.64,123.09,121.38,116.53,111.29,110.79,109.95,105.74,71.43,60.39,55.48,54.19,53.77,48.96,42.40,39.18,37.76,32.62,32.29,31.55,29.70,29.46,29.19,29.05,27.01,26.75,22.77,22.07,22.03,21.04,18.92,15.37,15.35,14.20.HRMS(DART-TOF)calculated for C52H67ClN9O8S[M+H]+m/z 1012.4522,found 1012.4512.
目标产物A4的合成：
Figure BDA0001722582780000172
该目标产物的原料为N-叔丁氧羰基-1,3-丙二胺以及中间体4，其它原料和操作方法同目标产物A1。得目标产物为黄色粉末，产率约为51％。
1H NMR(400MHz,CDCl3)δ＝9.52(s,1H),8.58(d,J＝8.3,1H),8.15(d,J＝6.5,1H),8.01(s,1H),7.93(dd,J＝8.0,1.5,1H),7.66–7.59(m,1H),7.56(s,1H),7.49(dd,J＝8.3,7.3,1H),7.35(t,J＝6.3,1H),7.27–7.23(m,1H),7.09(d,J＝7.0,1H),6.89(d,J＝8.5,1H),6.77(s,1H),6.49(t,J＝5.8,1H),4.98–4.85(m,1H),4.57(tp,J＝12.2,6.1,1H),3.52–3.41(m,2H),3.36(q,J＝6.5,2H),3.26(dt,J＝13.7,6.8,1H),3.07(s,2H),2.96(d,J＝11.4,2H),2.92–2.64(m,4H),2.33(dd,J＝11.5,9.7,2H),2.15(s,3H),2.14–2.07(m,1H),1.91(dq,J＝13.4,6.6,2H),1.83–1.64(m,5H),1.39–1.30(m,13H).13C NMR(101MHz,CDCl3)δ＝171.13,171.04,169.41,168.34,167.55,157.48,155.36,146.72,144.74,138.51,137.24,136.17,134.63,132.63,131.29,127.88,127.31,124.90,123.61,123.11,120.90,116.45,111.59,111.13,110.26,105.85,71.82,62.06,55.48,55.13,48.92,40.08,37.66,36.47,32.95,31.43,29.79,29.70,22.77,22.29,18.94,15.37.HRMS(DART-TOF)calculated for C46H55ClN9O8S[M+H]+m/z 928.3583,found 928.3581.
目标产物A5的合成：
Figure BDA0001722582780000181
该目标产物的原料为中间体A1-M以及中间体4，其它原料和操作方法同目标产物A1。得目标产物为黄色粉末，产率约为49％。
1H NMR(400MHz,CDCl3)δ＝9.52(s,1H),8.59(d,J＝8.2,1H),8.15(d,J＝6.5,1H),8.00(s,1H),7.93(dd,J＝8.0,1.5,1H),7.65–7.59(m,1H),7.58(s,1H),7.47(dt,J＝12.5,6.3,1H),7.27–7.21(m,1H),7.07(t,J＝6.9,1H),6.89(d,J＝8.5,1H),6.78(s,1H),6.25(t,J＝5.7,1H),4.89(dd,J＝12.1,5.3,1H),4.57(tp,J＝12.2,6.1,1H),3.43–3.22(m,5H),3.05(s,2H),2.96(d,J＝11.4,2H),2.90–2.62(m,4H),2.32(t,J＝10.9,2H),2.15(s,3H),1.82–1.64(m,9H),1.39–1.31(m,12H).13C NMR(101MHz,CDCl3)δ＝171.05,170.65,169.55,168.40,167.54,157.49,155.36,155.33,146.85,144.75,138.50,137.32,136.19,134.64,132.51,131.28,127.89,127.37,124.89,123.61,123.11,120.95,116.61,111.59,111.27,110.06,105.85,71.90,62.09,55.48,55.09,48.90,42.19,38.42,37.65,32.92,31.41,29.70,27.43,26.64,22.78,22.28,18.93,15.37,14.20.HRMS(DART-TOF)calculated for C47H57ClN9O8S[M+H]+m/z 942.3739,found 942.3731.
目标产物A6的合成：
Figure BDA0001722582780000182
该目标产物的原料为中间体A2-M以及中间体4，其它原料和操作方法同目标产物A1。得目标产物为黄色粉末，产率约为43％。
1H NMR(400MHz,CDCl3)δ＝9.53(s,1H),8.59(d,J＝8.1,1H),8.17(s,1H),7.98(s,1H),7.93(dd,J＝8.0,1.5,1H),7.60(dd,J＝13.0,5.9,2H),7.47(dd,J＝8.3,7.3,1H),7.27–7.20(m,3H),7.07(d,J＝7.0,1H),6.86(d,J＝8.5,1H),6.77(s,1H),6.22(t,J＝5.6,1H),4.98–4.84(m,1H),4.54(dq,J＝12.1,6.1,1H),3.27(dtt,J＝13.4,10.2,6.6,6H),3.05(s,2H),2.97(d,J＝11.2,2H),2.91–2.63(m,5H),2.32(t,J＝11.4,2H),2.15(s,3H),1.83–1.54(m,12H),1.37–1.30(m,15H).13C NMR(101MHz,CDCl3)δ＝171.16,170.43,169.55,168.55,167.61,157.49,155.38,155.26,146.93,144.85,138.50,137.38,136.11,134.62,132.53,131.28,127.80,127.23,124.88,123.62,123.10,121.07,116.57,111.42,111.13,109.97,105.80,71.72,62.07,60.39,55.48,55.02,48.92,42.54,38.78,37.60,33.00,32.96,31.93,31.45,29.78,29.69,29.36,29.21,26.72,26.64,22.79,22.69,22.21,21.04,18.92,15.36,14.20,14.12.HRMS(DART-TOF)calculated for C49H51ClN9O8S[M+H]+m/z 970.4052,found 970.4038.
目标产物A7的合成：
Figure BDA0001722582780000191
该目标产物的原料为中间体A3-M以及中间体4，其它原料和操作方法同目标产物A1。得目标产物为黄色粉末，产率约为45％。
1H NMR(400MHz,CDCl3)δ＝9.53(s,1H),8.58(d,J＝7.8,1H),8.17(s,1H),7.98(s,1H),7.93(dd,J＝8.0,1.6,1H),7.65(s,1H),7.63–7.57(m,1H),7.47(dd,J＝8.3,7.3,1H),7.27(s,1H),7.23(dt,J＝8.3,4.1,1H),7.07(d,J＝6.9,1H),6.87(dd,J＝8.5,3.4,1H),6.77(s,1H),6.23(t,J＝5.6,1H),4.90(dt,J＝11.3,4.5,1H),4.61–4.50(m,1H),3.27(dp,J＝20.4,6.7,6H),3.04(s,2H),2.97(d,J＝11.4,2H),2.92–2.65(m,5H),2.32(dd,J＝11.6,9.8,2H),2.15(s,4H),1.83–1.49(m,11H),1.39–1.29(m,22H).13C NMR(101MHz,CDCl3)δ＝171.20,170.41,169.55,168.62,167.66,157.49,155.38,155.23,146.99,144.89,138.49,137.43,136.07,134.62,132.55,131.28,127.75,127.16,124.88,123.62,123.10,121.14,116.59,111.35,111.05,109.95,105.77,71.65,62.06,60.39,55.48,55.00,48.93,42.56,38.91,37.59,33.03,31.48,29.72,29.23,29.18,29.15,26.90,26.83,22.81,22.18,21.04,18.92,15.37,14.20.HRMS(DART-TOF)calculated forC51H65ClN9O8S[M+H]+m/z 998.4365,found 998.4349.
3、B系列PROTAC分子的结构与合成
Figure BDA0001722582780000201
中间体B1-M的合成：
Figure BDA0001722582780000202
在20mLNMP中，加入3-氟-N-(2,6-二氧代-3-哌啶基)邻苯二甲酰亚胺(128mg,0.5mmol),[2-(2-氨基乙氧基)乙基]氨基甲酸叔丁酯(102mg，0.5mmol)，DIPEA(129mg,1mmol),90℃下反应10h，TLC监测反应。反应完成后，在反应液中加入150mLEA混匀后，首先用10％柠檬酸溶液洗2次，每次20mL，后用饱和NaHCO3溶液洗2次，每次20mL，最后用饱和食盐水洗2次后用无水硫酸钠干燥，减压浓缩后用PE/EA分离体系进行柱层析分离。产物为黄色固体，产率约为69％。
1H NMR(400MHz,CDCl3)δ＝8.27(s,1H),7.57–7.45(m,1H),7.11(d,J＝7.1,1H),6.95(t,J＝17.6,1H),6.52(s,1H),5.16–4.83(m,2H),3.81–3.23(m,8H),3.03–2.58(m,3H),2.14(dd,J＝23.0,16.2,1H),1.44(d,J＝9.7,9H).HRMS(DART-TOF)calculated forC22H28N4O7Na[M+Na]+m/z 483.1856,found 483.1860.
中间体B2-M的合成：
Figure BDA0001722582780000203
在20mLNMP中，加入2-(2-(2-氨基乙氧基)乙氧基)乙基氨基甲酸叔丁酯(124mg，0.5mmol)，其他原料和操作方法同B1-M。得黄色粉末，产率约为64％。
1H NMR(400MHz,MeOD)δ＝7.44(ddd,J＝8.5,7.9,4.4,1H),7.04–6.89(m,2H),4.95(dd,J＝12.4,5.3,1H),3.62(dd,J＝7.1,3.2,2H),3.59–3.47(m,4H),3.41(t,J＝5.6,4H),3.21(dt,J＝3.2,1.6,1H),3.11(t,J＝5.6,2H),2.84–2.53(m,3H),2.07–1.95(m,1H),1.27(d,J＝29.5,9H).HRMS(DART-TOF)calculated for C24H33N4O8[M+H]+m/z 505.2298,found 505.2291.
中间体B3-M的合成：
在20mLNMP中，加入13-氨基-5,8,11-三氧杂-2-氮杂十三烷酸1,1-二甲基乙酯(146mg，0.5mmol)，其他原料和操作方法同B1-M。得黄色粉末，产率约为61％。
1H NMR(400MHz,MeOD)δ＝7.44(dt,J＝14.2,5.5,1H),7.04–6.92(m,2H),4.95(dd,J＝12.6,5.4,1H),3.62(t,J＝4.9,2H),3.56(s,4H),3.50(ddd,J＝9.2,6.5,3.9,4H),3.44–3.35(m,4H),3.27–3.17(m,2H),3.08(dd,J＝13.2,7.7,2H),2.83–2.54(m,3H),2.08–1.95(m,1H),1.32(s,9H).HRMS(DART-TOF)calculated for C26H37N4O9[M+H]+m/z549.2561,found 549.2553.
中间体B4-M的合成：
Figure BDA0001722582780000212
在20mLNMP中，加入16-氨基-5,8,11,14-四氧杂-2-氮杂十六烷酸1,1-二甲基乙酯(170mg，0.5mmol)，其他原料和操作方法同B1-M。得黄色粉末，产率约为63％。
1H NMR(400MHz,CDCl3)δ＝7.49(dd,J＝8.3,7.4,1H),7.10(d,J＝7.0,1H),6.92(d,J＝8.5,1H),4.91(dd,J＝12.1,5.3,1H),3.72(t,J＝5.4,2H),3.70–3.58(m,10H),3.54(t,J＝5.1,2H),3.47(q,J＝5.5,2H),3.30(d,J＝4.8,2H),2.94–2.66(m,3H),2.17–2.07(m,1H),1.44(s,9H).13C NMR(101MHz,CDCl3)δ＝171.03,169.26,168.34,167.60,156.04,146.88,136.04,132.55,116.79,111.67,110.35,70.80,70.67,70.62,70.47,70.27,69.49,48.88,42.42,31.42,29.70,28.44,22.83,14.11.HRMS(DART-TOF)calculated forC28H41N4O10S[M+H]+m/z 593.2823,found593.2815.
目标产物B1的合成：
Figure BDA0001722582780000221
将B1-M(92mg,0.2mmol)溶于5mL三氟乙酸中，常温搅拌5h。停止反应，在反应液中加入10mLDCM并减压浓缩，得棕色油状物。在该油状物中加入10mLDMF溶解，加入中间体2(63mg，0.1mmol)，HATU(45.6mg，0.12mmol),DIPEA(38.7mg，0.3mmol)。常温反应15h，TLC监测反应进度。反应完成后用30mL水淬灭反应，用EA萃取水层4次，合并有机层，用饱和食盐水反洗2次，用无水硫酸钠干燥，减压浓缩，用DCM/MeOH分离体系进行柱层析分离。产物为黄色粉末，产率约46％.
1H NMR(400MHz,CDCl3)δ＝9.49(s,1H),8.57(d,J＝8.3,1H),8.15(s,1H),7.97(s,1H),7.92(dd,J＝7.9,1.3,1H),7.67–7.58(m,1H),7.54(s,1H),7.53–7.47(m,1H),7.24(d,J＝7.8,1H),7.13(d,J＝7.1,1H),6.86(d,J＝8.5,1H),6.77(s,1H),4.89(dd,J＝11.9,5.6,1H),4.61–4.46(m,1H),3.80–3.21(m,12H),2.90–2.45(m,9H),2.24–2.10(m,5H),1.78(d,J＝13.2,3H),1.37–1.30(m,13H).13C NMR(101MHz,CDCl3)δ＝172.53,171.83,171.14,170.11,167.47,157.51,155.33,146.75,144.73,138.48,136.32,134.67,132.51,131.24,127.70,127.15,124.88,123.71,123.13,120.76,116.79,111.92,111.32,110.49,105.69,71.81,70.16,68.31,60.39,55.46,54.54,53.88,53.22,48.91,41.67,39.17,37.72,32.56,31.74,31.48,29.69,23.65,22.27,22.26,21.04,18.93,15.37,14.20.HRMS(DART-TOF)calculated for C48H59ClN9O9S[M+H]+m/z 972.3845,found 972.3887.
目标产物B2的合成：
Figure BDA0001722582780000222
称取原料B2-M(250mg，0.5mmol)，其它原料和操作方法同目标产物B1。得目标产物为黄色粉末，产率约为41％。
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.57(d,J＝8.3,1H),8.15(s,1H),8.00(d,J＝11.6,1H),7.92(d,J＝7.9,1H),7.65–7.54(m,3H),7.47(t,J＝7.8,1H),7.27–7.21(m,1H),7.08(d,J＝7.0,1H),6.88(t,J＝8.8,1H),6.75(d,J＝5.0,1H),6.52(t,J＝5.1,1H),4.92(dd,J＝11.9,5.7,1H),4.55(dt,J＝12.0,6.0,1H),3.77–3.57(m,7H),3.51–3.39(m,4H),3.37–3.29(m,2H),2.98(s,2H),2.79(ddd,J＝29.5,19.9,8.9,5H),2.60–2.42(m,4H),2.18–2.11(m,4H),1.84(s,4H),1.33(dd,J＝11.2,6.4,11H).13C NMR(101MHz,CDCl3)δ＝172.26,172.05,169.54,169.45,167.62,157.45,155.35,155.29,146.73,144.80,138.46,136.17,134.68,132.52,131.28,127.96,127.18,124.85,123.59,123.19,120.88,116.82,111.73,110.95,110.30,71.74,70.70,70.03,69.83,69.12,60.40,55.50,53.82,48.91,42.20,39.44,31.38,22.95,22.21,21.05,18.92,15.37,14.20.HRMS(DART-TOF)calculated for C50H63ClN9O10S[M+H]+m/z 1016.4107,found 1016.4116.
目标产物B3的合成：
称取原料B3-M(110mg，0.2mmol)，其它原料和操作方法同目标产物B1。得目标产物为黄色粉末，产率约为45％。
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.57(d,J＝8.4,1H),8.16(s,1H),7.99(d,J＝13.0,1H),7.92(d,J＝7.9,1H),7.83(s,1H),7.67–7.54(m,2H),7.46(t,J＝7.7,1H),7.27–7.20(m,1H),7.06(d,J＝7.0,1H),6.89(d,J＝8.6,1H),6.77(s,1H),6.46(d,J＝5.1,1H),4.93(dd,J＝11.7,5.7,1H),4.56(dt,J＝12.0,6.0,1H),3.78–3.52(m,12H),3.45(d,J＝4.7,4H),3.25(dd,J＝13.4,6.7,3H),2.95–2.65(m,7H),2.59–2.33(m,4H),2.17–2.11(m,3H),1.80(d,J＝21.0,4H),1.41–1.28(m,12H).13C NMR(101MHz,CDCl3)δ＝172.74,172.07,171.16,169.44,169.41,167.65,157.46,155.34,155.27,146.75,144.83,138.46,136.14,134.69,132.45,131.26,127.85,127.12,124.81,123.59,123.17,120.93,116.89,111.67,110.96,110.26,105.79,71.69,70.43,70.27,70.07,69.96,69.36,60.39,55.50,54.08,53.79,48.90,42.22,39.14,37.22,31.81,31.39,22.75,22.19,21.04,18.91,15.36,14.20.HRMS(DART-TOF)calculated for C52H67ClN9O11S[M+H]+m/z 1060.4369,found1060.4349.
目标产物B4的合成：
Figure BDA0001722582780000241
称取原料B4-M(120mg，0.2mmol)，其它原料和操作方法同目标产物B1。得目标产物为黄色粉末，产率约为47％。1H NMR(400MHz,MeOD)δ＝8.35(d,J＝8.5,1H),8.05(d,J＝1.5,1H),7.82(d,J＝8.0,1H),7.66(t,J＝6.0,1H),7.60–7.54(m,1H),7.43(ddd,J＝9.6,8.5,6.0,1H),7.26(t,J＝7.7,1H),7.03–6.88(m,2H),6.74(d,J＝3.8,1H),6.20–6.08(m,1H),5.00–4.90(m,1H),4.56–4.43(m,1H),3.66–3.25(m,15H),2.92–2.33(m,8H),2.09–1.99(m,3H),1.27–1.14(m,17H).HRMS(DART-TOF)calculated for C54H71ClN9O12S[M+H]+m/z1104.4631,found 1104.4629.
目标产物B5的合成：
Figure BDA0001722582780000242
该目标产物的制备方法同B1，原料为中间体4和B1-M，其他原料和处理方法相同。产率为35％
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.57(t,J＝6.7,1H),8.16(s,1H),8.01(d,J＝6.1,1H),7.93(dd,J＝8.0,1.4,1H),7.66–7.59(m,1H),7.54(s,1H),7.51–7.45(m,1H),7.42(t,J＝5.8,1H),7.25(d,J＝7.5,1H),7.10(d,J＝7.1,1H),6.93–6.86(m,1H),6.49(t,J＝5.6,1H),4.92–4.83(m,1H),4.54(dq,J＝12.1,6.0,1H),3.80–3.43(m,9H),3.26(dt,J＝13.7,6.8,1H),3.07(s,2H),2.98(d,J＝11.4,2H),2.87–2.63(m,4H),2.32(t,J＝11.0,2H),2.15(s,3H),2.10–2.02(m,2H),1.72(d,J＝15.4,5H),1.36–1.30(m,12H).13C NMR(101MHz,CDCl3)δ＝170.91,170.79,169.40,168.28,167.49,157.48,155.36,146.73,144.73,138.50,137.39,136.17,134.64,132.52,131.29,127.79,127.25,124.91,123.63,123.12,120.85,116.63,111.90,111.14,110.47,105.86,71.76,70.11,69.28,61.96,55.47,54.85,48.91,42.38,38.75,37.65,32.94,31.37,29.70,22.76,22.25,18.92,15.37.HRMS(DART-TOF)calculated for C47H57ClN9O9S[M+H]+m/z 958.3688,found958.3676.
目标产物B6的合成：
Figure BDA0001722582780000251
该目标产物的制备方法同B1，原料为中间体4和B2-M，其他原料和处理方法相同。产率为31％
1H NMR(400MHz,CDCl3)δ＝9.53(s,1H),8.58(d,J＝8.2,1H),8.16(s,1H),7.97(s,1H),7.93(dd,J＝8.0,1.6,1H),7.60(dd,J＝11.3,4.2,2H),7.49(ddd,J＝9.5,8.3,4.3,2H),7.27–7.21(m,2H),7.10(d,J＝7.1,1H),6.87(d,J＝8.5,1H),6.78(s,1H),6.50(t,J＝5.4,1H),4.89(dt,J＝11.4,5.8,1H),4.63–4.52(m,1H),3.78–3.61(m,10H),3.57–3.42(m,5H),3.31–3.23(m,1H),3.08(d,J＝16.4,2H),2.98(d,J＝8.6,2H),2.90–2.59(m,6H),2.30(t,J＝10.4,3H),2.13(d,J＝6.9,4H),1.70(dd,J＝20.5,10.9,5H),1.39–1.29(m,14H).13CNMR(101MHz,CDCl3)δ＝171.27,170.76,169.36,168.74,167.59,157.50,155.38,146.73,144.83,138.50,137.53,136.04,134.63,132.61,131.28,127.68,127.10,124.88,123.11,120.99,116.62,111.73,111.05,110.49,105.78,99.99,71.59,70.81,70.27,70.16,69.37,55.48,54.90,48.95,42.29,37.57,32.93,31.43,22.93,22.20,18.92,15.37.HRMS(DART-TOF)calculated for C49H61ClN9O10S[M+H]+m/z 1002.3951,found958.3676.
目标产物B7的合成：
Figure BDA0001722582780000252
该目标产物的制备方法同B1，原料为中间体4和B3-M，其他原料和处理方法相同。产率为27％
1H NMR(400MHz,CDCl3)δ＝9.52(s,1H),8.58(d,J＝7.9,1H),8.18(s,1H),7.97(s,1H),7.92(dd,J＝8.0,1.6,1H),7.67(s,1H),7.63–7.57(m,1H),7.47(dd,J＝8.3,7.3,1H),7.27–7.22(m,2H),7.09(d,J＝6.9,1H),6.89(d,J＝8.5,1H),6.78(s,1H),6.46(t,J＝5.6,1H),4.92(dt,J＝9.7,7.1,1H),4.64–4.53(m,1H),3.73–3.63(m,10H),3.59(t,J＝5.1,2H),3.51(dd,J＝10.5,5.2,2H),3.44(dd,J＝10.8,5.4,2H),3.25(dq,J＝13.7,6.9,1H),3.08(d,J＝14.6,2H),2.97(d,J＝11.0,2H),2.91–2.63(m,4H),2.30(t,J＝10.0,2H),2.14(s,3H),1.73(dd,J＝20.5,12.0,4H),1.37–1.30(m,13H).13C NMR(101MHz,CDCl3)δ＝171.36,169.32,168.70,167.64,157.50,155.38,155.22,146.78,144.91,138.49,137.54,135.99,134.64,132.57,131.27,127.62,126.98,124.86,123.62,123.10,121.10,116.68,111.65,110.94,110.38,105.74,71.52,70.83,70.62,70.51,70.34,70.13,69.51,62.06,60.39,55.48,54.95,48.94,42.41,38.79,37.59,32.96,31.51,29.69,22.80,22.17,21.05,18.92,15.37,14.20.HRMS(DART-TOF)calculated for C51H65ClN9O11S[M+H]+m/z1046.4213,found 1046.4213.
4、C系列PROTAC分子的结构与合成
中间体C-M的合成：
称取泊马度胺(546mg，2mmol),溶于100mLTHF中，加入氯乙酰氯(452mg，4mmol),回流5h，用TLC监测反应。先减压浓缩，除去THF，用200mL的EA溶解，后用水反洗3次。有机层用无水硫酸钠干燥，减压浓缩，用PE/EA作为流动相进行柱层析分离。得白色固体，产率约为70％。
1H NMR(400MHz,CDCl3)δ＝8.78(t,J＝12.7,1H),7.80–7.70(m,1H),7.60(d,J＝7.3,1H),4.97(dd,J＝12.4,5.3,1H),3.98–3.85(m,2H),3.02–2.68(m,3H),2.20(ddd,J＝12.4,10.1,6.3,1H).HRMS(DART-TOF)calculated for C15H13ClN3O5[M+H]+m/z 350.0544,found 350.0537.
中间体C1-M的合成：
Figure BDA0001722582780000271
称取中间体C-M(70mg，0.2mmol),溶于10mL THF中，加入N-叔丁氧羰基-1,4-丁二胺(113mg，0.6mmol),碳酸钾(83mg，0.6mmol),回流5h，用TLC监测反应。加入30mL水淬灭反应，用100mL的EA萃取3次，后用水反洗3次。有机层用无水硫酸钠干燥，减压浓缩，用PE/EA作为流动相进行柱层析分离。得黄色固体，产率约为70％。
1H NMR(400MHz,CDCl3)δ＝11.24(d,J＝20.3,1H),8.90(d,J＝8.4,1H),7.79–7.66(m,1H),7.55(t,J＝10.5,1H),5.22–4.73(m,2H),3.20(dddd,J＝94.9,67.2,44.2,26.5,9H),2.18(s,1H),1.65–1.36(m,12H).HRMS(DART-TOF)calculated for C24H32N5O7[M+H]+m/z 502.2302,found 502.2293.
中间体C2-M的合成：
Figure BDA0001722582780000272
该中间体的制备方法同C1-M，原料为N-叔丁氧羰基-1,6-己二胺，其他原料和处理方法相同。产率为65％
1H NMR(400MHz,CDCl3)δ＝8.91(d,J＝8.5,1H),7.75–7.68(m,1H),7.57(t,J＝5.8,1H),4.99(dd,J＝12.2,5.2,1H),3.46(dd,J＝33.9,17.4,2H),3.24–2.56(m,7H),2.28–2.10(m,1H),1.65(dd,J＝52.8,47.1,4H),1.44(s,10H),1.39–1.19(m,8H).HRMS(DART-TOF)calculated for C26H36N5O7[M+H]+m/z 530.2615,found 530.2606.
中间体C3-M的合成：
Figure BDA0001722582780000281
该中间体的制备方法同C1-M，原料为N-叔丁氧羰基-1,8-辛二胺，其他原料和处理方法相同。产率为61％
1H NMR(400MHz,CDCl3)δ＝8.96–8.73(m,1H),7.73(dt,J＝11.9,7.9,1H),7.63–7.52(m,1H),4.98(dt,J＝12.5,11.2,1H),3.56–3.44(m,1H),3.11(t,J＝17.3,2H),2.96–2.61(m,4H),2.16(dt,J＝10.2,6.2,1H),1.91(d,J＝47.5,2H),1.57(dd,J＝13.9,6.9,1H),1.44(s,9H),1.38–1.20(m,10H).HRMS(DART-TOF)calculated for C28H40N5O7[M+H]+m/z 558.2928,found558.2921.
目标产物C1的合成：
Figure BDA0001722582780000282
将C1-M(92mg,0.2mmol)溶于5mL三氟乙酸中，50℃下搅拌1h。停止反应，在反应液中加入10mLDCM并减压浓缩，得棕色油状物。在该油状物中加入10mLDMF溶解，加入中间体2(63mg，0.1mmol)，HATU(45.6mg，0.12mmol),DIPEA(38.7mg，0.3mmol)。常温反应15h，TLC监测反应进度。反应完成后用30mL水淬灭反应，用EA萃取水层4次，合并有机层，用饱和食盐水反洗2次，用无水硫酸钠干燥，减压浓缩，用DCM/MeOH分离体系进行柱层析分离。产物为黄色粉末，产率约46％.
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.89(d,J＝8.4,0H),8.57(d,J＝8.3,1H),8.16(s,1H),8.01(d,J＝4.5,1H),7.93(d,J＝7.8,1H),7.75–7.65(m,1H),7.65–7.59(m,1H),7.55(d,J＝6.7,1H),7.25(d,J＝9.3,3H),6.80–6.72(m,1H),5.06–4.86(m,1H),4.55(dd,J＝12.0,5.9,1H),3.30(ddd,J＝20.4,15.4,7.6,6H),3.00–2.61(m,7H),2.21–2.13(m,3H),1.97–1.49(m,11H),1.38–1.29(m,13H).HRMS(DART-TOF)calculated forC50H62ClN10O9S[M+H]+m/z1013.4110,found 1013.4182.
目标产物C2的合成：
Figure BDA0001722582780000291
该目标产物的制备方法同C1，原料为C2-M，其他原料和处理方法相同。产率为45％
1H NMR(400MHz,CDCl3)δ＝11.12(s,1H),9.44(s,1H),8.83(d,J＝8.4,1H),8.50(d,J＝8.2,1H),8.09(s,1H),7.92(s,1H),7.86(d,J＝7.8,1H),7.63(t,J＝7.7,1H),7.58–7.44(m,3H),7.18(d,J＝11.8,2H),6.70(s,1H),4.90(dd,J＝11.6,5.1,1H),4.47(dt,J＝11.7,5.8,1H),3.35(q,J＝17.6,2H),3.27–3.06(m,5H),2.95–2.51(m,10H),2.43(s,2H),2.19(s,3H),2.07(s,3H),1.74(s,4H),1.47(ddd,J＝22.2,16.0,7.8,6H),1.26(dd,J＝13.5,6.4,12H).13C NMR(101MHz,CDCl3)δ＝172.01,171.73,168.63,168.33,166.98,157.45,155.29,144.78,138.48,137.08,136.13,134.63,131.52,131.28,127.88,127.11,125.16,124.94,123.63,123.13,120.87,118.43,116.02,111.01,105.86,100.00,71.74,60.40,55.47,54.10,53.81,53.53,50.44,49.27,39.24,37.59,32.42,31.57,29.96,29.54,26.96,26.77,22.74,22.22,18.92,15.37,14.20.HRMS(DART-TOF)calculated forC52H66ClN10O9S[M+H]+m/z 1041.4423,found 1041.4438.
目标产物C3的合成：
Figure BDA0001722582780000292
该目标产物的制备方法同C1，原料为C3-M，其他原料和处理方法相同。产率为48％。
1H NMR(400MHz,CDCl3)δ＝9.52(s,1H),8.58(d,J＝8.3,1H),8.17(d,J＝6.8,1H),8.17(d,J＝6.8,1H),8.01(d,J＝9.4,1H),7.93(d,J＝7.9,1H),7.71(dt,J＝12.6,6.4,1H),7.66–7.50(m,3H),7.24(d,J＝7.7,1H),4.96(dd,J＝12.0,5.1,1H),4.52(dd,J＝12.0,5.9,1H),3.57–3.38(m,2H),3.33–3.13(m,5H),2.95–2.40(m,10H),2.28(s,2H),2.15(s,3H),1.96(d,J＝6.3,2H),1.90–1.70(m,5H),1.32(ddd,J＝26.8,14.8,6.7,27H).HRMS(DART-TOF)calculated for C54H70ClN10O9S[M+H]+m/z 1069.4736,found 1069.4791.
5、D系列PROTAC分子的结构与合成：
中间体D1-M的合成：
Figure BDA0001722582780000301
该中间体的制备方法同C1-M，原料为[2-(2-氨基乙氧基)乙基]氨基甲酸叔丁酯，其它原料和处理方法相同。产率为61％
1H NMR(400MHz,CDCl3)δ＝11.19(s,1H),8.90(d,J＝8.5,1H),7.76–7.67(m,1H),7.56(d,J＝7.2,1H),4.99(s,2H),3.65(dd,J＝12.5,7.6,2H),3.53(dd,J＝11.4,6.1,4H),3.32(d,J＝4.8,2H),2.96–2.74(m,5H),2.26–2.11(m,2H),1.41(d,J＝26.9,9H).13C NMR(101MHz,CDCl3)δ＝171.79,171.11,168.44,166.92,156.10,137.06,136.24,131.44,125.22,118.52,116.04,77.37,77.05,76.73,70.19,70.12,60.40,53.18,49.50,49.25,40.36,31.39,29.68,28.41,22.69,21.04,14.19.HRMS(DART-TOF)calculated forC24H31N5O8Na[M+Na]+m/z 540.2070,found540.2117.
中间体D2-M的合成：
Figure BDA0001722582780000302
该中间体的制备方法同C1-M，原料为2-(2-(2-氨基乙氧基)乙氧基)乙基氨基甲酸叔丁酯，其它原料和处理方法相同，产率为67％。
1H NMR(400MHz,CDCl3)δ＝11.21(s,1H),8.90(d,J＝8.5,1H),7.71(t,J＝7.9,1H),7.54(t,J＝10.0,1H),4.98(dd,J＝11.8,5.3,1H),3.71(dd,J＝11.9,7.2,2H),3.63(s,4H),3.53(dd,J＝10.2,5.2,2H),3.48(d,J＝17.6,2H),2.97–2.69(m,5H),2.15(dd,J＝16.4,11.8,3H),1.43(s,10H).13C NMR(101MHz,CDCl3)δ＝171.87,171.17,168.37,166.92,156.06,137.10,136.22,131.43,125.23,118.48,116.02,79.31,77.37,77.05,76.74,70.38,70.28,70.24,70.13,60.39,53.06,49.42,49.23,40.35,31.40,29.68,28.41,22.67,21.03,14.19.HRMS(DART-TOF)calculated for C26H36N5O9[M+H]+m/z 562.2513,found 562.2510.
中间体D3-M的合成：
Figure BDA0001722582780000311
该中间体的制备方法同C1-M，原料为13-氨基-5,8,11-三氧杂-2-氮杂十三烷酸1,1-二甲基乙酯，其它原料和处理方法相同，产率为59％。
1H NMR(400MHz,CDCl3)δ＝11.15(s,1H),8.78(dd,J＝15.0,8.2,1H),7.66–7.60(m,1H),7.46(d,J＝7.3,1H),4.92(dt,J＝9.4,8.7,1H),3.81–3.32(m,16H),3.22(d,J＝4.5,2H),2.89–2.63(m,5H),2.39(s,2H),1.35(s,9H).13C NMR(101MHz,CDCl3)δ＝172.01,171.57,171.13,168.44,168.31,166.93,156.03,137.02,136.13,131.40,125.09,118.37,115.98,79.10,70.39,70.37,70.30,70.22,70.19,60.34,52.99,49.34,49.20,40.28,31.36,29.61,28.38,22.61,20.98,14.15.HRMS(DART-TOF)calculated for C28H40N5O10[M+H]+m/z 606.2775,found 606.2772.
目标产物D1的合成：
Figure BDA0001722582780000312
该目标产物制备方法同C1，原料为D1-M，其它原料和处理方法相同，产率为47％。
1H NMR(400MHz,CDCl3)δ＝11.18(s,1H),9.51(s,1H),8.87(d,J＝8.5,1H),8.58(d,J＝8.3,1H),8.14(d,J＝11.3,1H),7.99(s,1H),7.92(dd,J＝7.9,1.3,1H),7.75–7.66(m,1H),7.65–7.58(m,1H),7.58–7.50(m,2H),7.25(d,J＝7.6,1H),6.77(s,1H),4.96(dd,J＝12.1,5.4,1H),4.60–4.48(m,1H),3.78–3.53(m,4H),3.53–3.38(m,4H),3.34–3.07(m,4H),2.96–2.61(m,9H),2.47(t,J＝6.4,2H),2.15(s,3H),1.88–1.61(m,5H),1.38–1.30(m,13H).13C NMR(101MHz,CDCl3)δ＝172.72,171.80,171.45,168.55,168.50,166.89,157.47,155.34,144.76,138.49,137.02,136.23,134.65,131.47,131.27,127.85,127.25,125.14,124.87,123.62,123.12,120.87,118.53,116.03,111.18,105.83,71.83,70.23,69.83,60.40,55.47,54.12,53.99,53.83,53.30,49.57,49.28,39.02,37.83,32.45,31.42,29.69,22.83,22.69,22.26,21.04,18.92,15.37,14.20,14.12.HRMS(DART-TOF)calculated for C50H60ClN10O10S[M+H]+m/z 1029.4060,found 1029.4071.
目标产物D2的合成：
Figure BDA0001722582780000321
该目标产物制备方法同C1，原料为D2-M，其它原料和处理方法相同，产率为51％。
1H NMR(400MHz,CDCl3)δ＝11.21(s,1H),9.50(s,1H),8.88(d,J＝8.5,1H),8.57(d,J＝8.4,1H),8.14(s,1H),7.97(s,1H),7.92(d,J＝7.5,2H),7.75–7.66(m,1H),7.66–7.57(m,2H),7.55(d,J＝7.2,1H),7.24(d,J＝7.6,1H),6.78(s,1H),4.96(dd,J＝12.1,5.3,1H),4.54(dt,J＝12.1,6.0,1H),3.77–3.38(m,14H),3.26(dt,J＝13.7,6.8,1H),3.13(d,J＝11.2,2H),2.97–2.61(m,10H),2.45(t,J＝6.5,2H),2.15(d,J＝6.4,7H),1.75(d,J＝11.4,5H),1.38–1.29(m,14H).13C NMR(101MHz,CDCl3)δ＝172.51,171.91,171.40,168.49,168.45,166.92,157.47,155.34,155.26,144.80,138.48,137.41,137.08,136.19,134.66,131.45,131.26,127.70,127.09,125.15,124.86,123.63,123.11,120.88,118.45,116.01,111.12,105.76,71.67,70.55,70.23,70.06,69.97,55.47,54.20,53.91,53.18,49.40,49.30,38.97,37.95,32.85,32.52,31.52,29.69,22.71,22.22,18.93,15.36,14.20.HRMS(DART-TOF)calculated for C52H66ClN10O11S[M+H]+m/z 1073.4322,found1073.4313.
目标产物D3的合成：
Figure BDA0001722582780000322
该目标产物制备方法同C1，原料为D3-M，其它原料和处理方法相同，产率为49％。
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.77(d,J＝7.7,1H),8.56(d,J＝8.2,1H),8.15(s,1H),7.99(s,1H),7.92(d,J＝8.1,1H),7.68(d,J＝7.3,1H),7.65–7.59(m,1H),7.55(d,J＝11.0,1H),7.52(s,1H),7.29–7.21(m,4H),6.74(s,1H),4.63–4.51(m,1H),3.64(s,10H),3.53(s,2H),3.39(d,J＝6.8,4H),3.05(s,2H),2.84(s,6H),2.57(s,4H),2.13(s,5H),1.87(s,7H),1.32(dd,J＝11.0,6.4,12H).HRMS(DART-TOF)calculated forC54H70ClN10O12S[M+H]+m/z 1117.4584,found 1117.4648.
6、E系列PROTAC分子的结构及合成：
Figure BDA0001722582780000331
中间体E-M的制备：
称取泊马度胺(546mg，2mmol),溶于100mLTHF中，加入丙烯酰氯(362mg，4mmol),回流5h，用TLC监测反应。先减压浓缩，除去THF，用200mL的EA溶解，后用水反洗3次。有机层用无水硫酸钠干燥，减压浓缩，用PE/EA作为流动相进行柱层析分离。得黄色固体，产率约为70％。
1H NMR(400MHz,CDCl3)δ＝9.54(d,J＝37.5,1H),8.91(d,J＝8.5,1H),8.03(s,1H),7.82–7.69(m,1H),7.58(d,J＝7.2,1H),6.48(d,J＝17.0,1H),6.31(dd,J＝17.0,10.3,1H),5.89(d,J＝10.3,1H),4.96(dd,J＝12.3,5.4,1H),2.84(dddd,J＝36.3,29.1,14.4,3.6,3H),2.27–2.13(m,1H).HRMS(DART-TOF)calculated for C16H14N3O5[M+H]+m/z328.0928,found 328.0919.
中间体E1-M的合成：
Figure BDA0001722582780000341
称取E-M(65mg,0.2mmol)，溶于10mL的THF中，加入N-叔丁氧羰基-1,4-丁二胺(56.5mg,0.3mmol)，三乙胺(60mg，0.6mmol)。40℃下反应12小时，TLC监测反应。反应完全后，加入30mL水淬灭反应，用EA萃取水层4次，合并有机层，用饱和食盐水反洗2次，用无水硫酸钠干燥，减压浓缩，用DCM/MeOH分离体系进行柱层析分离。产物为黄色粉末，产率约52％.
1H NMR(400MHz,CDCl3)δ＝8.76(dd,J＝16.2,8.5,1H),7.74–7.65(m,1H),7.56(t,J＝8.7,1H),4.97(s,1H),3.28–2.51(m,13H),1.53–1.36(m,13H).HRMS(DART-TOF)calculated for C25H34N5O7[M+H]+m/z 516.2750,found 516.2460.
中间体E2-M的合成：
Figure BDA0001722582780000342
该中间体的制备方法同E1-M，原料为N-叔丁氧羰基-1,6-己二胺，其他原料和处理方法相同。产率为48％
1H NMR(400MHz,CDCl3)δ＝8.77(d,J＝8.4,1H),7.69(t,J＝7.9,1H),7.54(d,J＝7.3,1H),5.00–4.92(m,1H),3.24–2.60(m,13H),1.39(d,J＝41.4,19H).HRMS(DART-TOF)calculated for C27H38N5O7[M+H]+m/z 544.2771,found 544.2775.
中间体E3-M的合成：
Figure BDA0001722582780000343
该中间体的制备方法同E1-M，原料为N-叔丁氧羰基-1,8-辛二胺，其他原料和处理方法相同。产率为48％
1H NMR(400MHz,CDCl3)δ＝8.70(t,J＝9.7,1H),7.63(dd,J＝17.9,10.4,1H),7.48(t,J＝9.5,1H),3.14–2.56(m,13H),2.12–2.02(m,1H),1.42–1.19(m,23H).HRMS(DART-TOF)calculated for C29H42N5O7[M+H]+m/z 572.3084,found 572.3110.
目标产物E1的合成：
Figure BDA0001722582780000351
将E1-M(103mg,0.2mmol)溶于5mL三氟乙酸中，50℃下搅拌1h。停止反应，在反应液中加入10mLDCM并减压浓缩，得棕色油状物。在该油状物中加入10mLDMF溶解，加入中间体2(63mg，0.1mmol)，HATU(45.6mg，0.12mmol),DIPEA(38.7mg，0.3mmol)。常温反应15h，TLC监测反应进度。反应完成后用30mL水淬灭反应，用EA萃取水层4次，合并有机层，用饱和食盐水反洗2次，用无水硫酸钠干燥，减压浓缩，用DCM/MeOH分离体系进行柱层析分离。产物为黄色粉末，产率约46％.
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.81–8.65(m,1H),8.56(t,J＝9.4,1H),8.20–8.10(m,1H),8.08–7.98(m,1H),7.93(d,J＝7.5,1H),7.71(d,J＝5.2,1H),7.67–7.48(m,3H),7.24(s,1H),6.80(d,J＝10.0,1H),4.96(s,1H),4.57(s,1H),3.77(dd,J＝22.6,16.6,2H),3.60–3.12(m,7H),2.81(dd,J＝91.0,52.5,8H),2.14(d,J＝4.9,3H),2.09–1.52(m,14H),1.40–1.28(m,16H).HRMS(DART-TOF)calculated for C51H64ClN10O9S[M+H]+m/z1027.4267,found1027.4261.
目标产物E2的合成：
该目标产物制备方法同E1，原料为E1-M，其它原料和处理方法相同，产率为31％。
1H NMR(400MHz,CDCl3)δ＝9.52(d,J＝6.6,1H),8.57(t,J＝8.6,1H),8.16(d,J＝1.8,1H),8.05(d,J＝13.6,1H),7.93(dd,J＝8.0,1.5,1H),7.62(t,J＝7.9,1H),7.56(d,J＝4.2,1H),7.36–7.25(m,4H),6.74(d,J＝8.0,1H),4.60(td,J＝12.5,6.3,1H),4.05–3.95(m,1H),3.77(d,J＝13.4,1H),3.54(s,1H),3.34–2.89(m,5H),2.84–2.67(m,1H),2.20(dd,J＝24.5,6.7,3H),2.10(s,1H),1.94–1.49(m,8H),1.40–1.21(m,24H).HRMS(DART-TOF)calculated for C53H68ClN10O9S[M+H]+m/z 1055.4580,found 1055.4595.
7、F系列PROTAC分子的结构及合成
Figure BDA0001722582780000361
中间体F1-M的合成：
该中间体的制备方法同E1-M，原料为[2-(2-氨基乙氧基)乙基]氨基甲酸叔丁酯，其他原料和处理方法相同，产率为53％
1H NMR(400MHz,CDCl3)δ＝8.80(t,J＝8.4,1H),7.69(dd,J＝8.5,7.4,1H),7.55(d,J＝7.2,1H),4.96(d,J＝6.1,1H),3.69–3.59(m,2H),3.53(t,J＝5.3,2H),3.31(d,J＝4.2,2H),3.06(t,J＝5.9,2H),2.96–2.85(m,3H),2.82–2.73(m,2H),2.68(t,J＝6.0,2H),2.22–2.08(m,1H),1.43(d,J＝6.8,10H).HRMS(DART-TOF)calculated for C25H34N5O8[M+H]+m/z 532.2407,found532.2399.
中间体F2-M的合成：
该中间体的制备方法同E1-M，原料为2-(2-(2-氨基乙氧基)乙氧基)乙基氨基甲酸叔丁酯，其他原料和处理方法相同，产率为41％。
1H NMR(400MHz,CDCl3)δ＝8.77(t,J＝12.7,1H),7.68(dt,J＝22.9,11.4,1H),7.53(t,J＝9.2,1H),5.20(s,1H),5.01–4.90(m,1H),3.68(dd,J＝10.0,5.1,2H),3.64(d,J＝8.6,4H),3.54(t,J＝5.1,2H),3.31(d,J＝4.3,2H),3.09(t,J＝5.8,2H),3.00–2.67(m,7H),2.21–2.08(m,1H),1.43(s,9H).HRMS(DART-TOF)calculated for C27H38N5O9[M+H]+m/z576.2670,found576.2665.
目标产物F1的合成：
该目标产物制备方法同E1，原料为F1-M，其它原料和处理方法相同，产率为39％。
1H NMR(400MHz,CDCl3)δ＝9.52(s,1H),8.79(d,J＝8.2,1H),8.58(d,J＝8.0,1H),8.16(s,1H),8.05–7.97(m,1H),7.93(dd,J＝8.0,1.5,1H),7.70–7.64(m,1H),7.64–7.58(m,1H),7.57(s,1H),7.53(d,J＝6.8,1H),7.26–7.23(m,1H),6.77(s,1H),4.94(dd,J＝12.4,5.4,1H),4.54(dt,J＝12.1,6.1,1H),3.71–3.54(m,4H),3.49–3.43(m,2H),3.29–3.18(m,2H),3.04(t,J＝5.9,2H),2.78(dddd,J＝21.3,18.4,10.7,5.0,9H),2.53(t,J＝6.2,2H),2.14(s,3H),1.80(s,3H),1.33(dd,J＝11.8,6.4,10H).13C NMR(101MHz,CDCl3)δ＝172.27,171.65,171.41,168.53,168.53,168.26,166.84,157.45,155.35,144.80,138.49,137.33,136.04,134.64,134.64,131.48,131.28,127.94,127.94,127.12,126.18,124.89,123.60,123.13,120.85,118.47,116.18,111.07,105.88,71.79,69.74,55.48,53.86,49.25,48.77,44.77,39.07,37.43,31.93,31.45,29.70,29.36,22.69,22.24,18.93,15.37,14.12.HRMS(DART-TOF)calculated for C51H64ClN10O10S[M+H]+m/z1043.4216,found 1043.4178.
目标产物F2的合成：
Figure BDA0001722582780000372
该目标产物制备方法同E1，原料为F2-M，其它原料和处理方法相同，产率为31％。
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.82(d,J＝8.0,1H),8.58(d,J＝8.3,1H),8.17–8.13(m,1H),8.00(dd,J＝8.6,4.2,1H),7.93(dd,J＝8.0,1.5,1H),7.68(dd,J＝8.5,7.3,1H),7.65–7.58(m,2H),7.53(d,J＝6.7,1H),7.26–7.22(m,1H),6.78(d,J＝4.4,1H),5.01–4.88(m,1H),4.55(dt,J＝12.2,6.0,1H),3.79–3.36(m,13H),3.25(dd,J＝13.1,6.2,1H),3.13(d,J＝10.7,2H),3.04–2.98(m,1H),2.92–2.83(m,2H),2.82–2.69(m,4H),2.62–2.55(m,1H),2.46(t,J＝6.5,2H),2.25–2.11(m,6H),1.76(d,J＝17.4,8H),1.39–1.31(m,12H).13C NMR(101MHz,CDCl3)δ＝172.05,171.32,168.47,168.21,166.85,157.49,155.35,144.80,138.51,137.49,137.31,136.04,134.64,131.28,127.73,127.16,127.07,126.27,124.88,123.64,123.10,118.39,116.15,111.12,71.68,70.20,70.13,70.00,55.47,53.99,48.74,44.83,38.95,37.93,37.30,32.88,32.47,31.93,29.70,29.36,22.69,22.23,18.94,15.37.HRMS(DART-TOF)calculated for C53H68ClN10O11S[M+H]+m/z1087.4478,found 1087.4503.
8、G系列的PROTAC的结构与合成
Figure BDA0001722582780000381
中间体G-M的合成：
Figure BDA0001722582780000391
称取3-氨基-N-(2,6-二氧代-3-哌啶基)邻苯二甲酰亚胺(411mg,0.15mmol)溶于DMF中，加入溴乙酸叔丁酯(293mg,0.15mmol)，碳酸钾(621mg，4.5mmol)，常温搅拌15h，TLC监测反应，反应完全后在反应液中加入30mL水淬灭反应，用EA萃取水层4次，合并有机层，用饱和食盐水反洗2次，用无水硫酸钠干燥，减压浓缩，用PE/EA分离体系进行柱层析分离。产物为白色粉末，产率约72％.
1H NMR(400MHz,CDCl3)δ＝7.67(dd,J＝8.4,7.4,1H),7.52(d,J＝7.1,1H),7.11(d,J＝8.4,1H),4.97(dd,J＝12.2,5.3,1H),4.77(d,J＝16.7,2H),3.02–2.63(m,4H),1.48(s,8H).HRMS(DART-TOF)calculated for C19H21N2O7[M+H]+m/z 389.1349,found389.1339.
中间体G1-M的合成：
Figure BDA0001722582780000392
将G-M(78mg,0.2mmol)溶于5mL三氟乙酸中，50℃下搅拌1h。停止反应，在反应液中加入10mLDCM并减压浓缩，得白色固体，加入10mLDMF溶解，加入N-叔丁氧羰基-1,4-丁二胺(54mg，0.3mmol)，HATU(91mg，0.24mmol),DIPEA(38.7mg，0.3mmol)。常温反应15h，TLC监测反应进度。反应完成后用30mL水淬灭反应，用EA萃取水层4次，合并有机层，用饱和食盐水反洗2次，用无水硫酸钠干燥，减压浓缩，用DCM/MeOH分离体系进行柱层析分离。产物为黄色粉末，产率约56％.
1H NMR(400MHz,CDCl3)δ＝7.76(dd,J＝8.3,7.4,1H),7.57(d,J＝7.3,1H),7.22(d,J＝8.4,1H),5.01(d,J＝6.0,1H),4.79–4.55(m,2H),3.56(s,1H),3.21(s,2H),2.99–2.70(m,3H),2.17(qd,J＝5.6,2.9,1H),1.65–1.51(m,4H),1.44(d,J＝15.5,8H).HRMS(DART-TOF)calculated for C24H30N4O7K[M+H]+m/z 525.1752,found 525.1985.
中间体G2-M的合成：
Figure BDA0001722582780000401
该中间体的制备方法同G1-M，原料为N-叔丁氧羰基-1,6-己二胺，其他原料和处理方法相同。产率为68％
1H NMR(400MHz,CDCl3)δ＝7.75(dd,J＝8.3,7.4,1H),7.55(d,J＝7.1,1H),7.21(d,J＝8.4,1H),4.64(s,3H),3.49–3.15(m,4H),2.97–2.72(m,4H),1.70–1.55(m,5H),1.30–1.22(m,11H).HRMS(DART-TOF)calculated for C26H35N4O7[M+H]+m/z 515.2506,found 515.2501.
中间体G3-M的合成：
该中间体的制备方法同G1-M，原料为N-叔丁氧羰基-1,8-辛二胺，其他原料和处理方法相同。产率为57％
1H NMR(400MHz,CDCl3)δ＝7.74(dd,J＝8.3,7.5,1H),7.55(d,J＝7.2,1H),7.20(d,J＝8.3,1H),5.05–4.93(m,1H),4.64(s,2H),3.36(dd,J＝13.0,6.8,2H),3.27–3.16(m,1H),2.83(dddd,J＝20.9,16.1,10.6,2.9,4H),2.16(dt,J＝9.8,6.4,1H),1.44(s,13H),1.30(s,9H).HRMS(DART-TOF)calculated for C28H39N4O8[M+H]+m/z 559.2768,found559.2761.
目标产物G1的合成：
Figure BDA0001722582780000403
将G1-M(100mg,0.2mmol)溶于5mL三氟乙酸中，50℃下搅拌1h。停止反应，在反应液中加入10mLDCM并减压浓缩，得棕色油状物。在该油状物中加入10mLDMF溶解，加入中间体2(63mg，0.1mmol)，HATU(45.6mg，0.12mmol),DIPEA(38.7mg，0.3mmol)。常温反应15h，TLC监测反应进度。反应完成后用30mL水淬灭反应，用EA萃取水层4次，合并有机层，用饱和食盐水反洗2次，用无水硫酸钠干燥，减压浓缩，用DCM/MeOH分离体系进行柱层析分离。产物为黄色粉末，产率约39％.
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.58(d,J＝8.0,1H),8.16(s,1H),8.00(s,1H),7.93(dd,J＝8.0,1.5,1H),7.73(dd,J＝8.3,7.4,1H),7.66–7.59(m,2H),7.55(s,2H),7.27–7.23(m,1H),7.19(d,J＝8.3,1H),6.77(s,1H),5.05–4.93(m,1H),4.60(dt,J＝12.2,10.2,3H),3.32(dddd,J＝34.8,27.9,13.6,7.1,7H),2.98–2.64(m,6H),2.50(d,J＝6.2,2H),2.14(s,3H),1.78(d,J＝18.6,4H),1.70–1.53(m,4H),1.42–1.29(m,12H).13C NMR(101MHz,CDCl3)δ＝171.49,168.82,166.81,166.59,166.45,157.48,155.34,154.76,144.74,138.50,137.12,134.65,133.51,131.27,127.85,127.10,124.89,123.63,123.12,120.79,120.33,118.41,117.63,111.03,105.83,71.80,68.66,60.39,55.48,53.92,53.78,49.44,38.84,38.75,32.14,31.53,26.83,26.62,22.79,22.24,21.04,18.92,15.37,14.20.HRMS(DART-TOF)calculated for C50H61ClN9O10S[M+H]+m/z 1014.3951,found1014.3975.
目标产物G2的合成：
Figure BDA0001722582780000411
该目标产物制备方法同G1，原料为G2-M，其它原料和处理方法相同，产率为28％。
1H NMR(400MHz,CDCl3)δ＝9.52(s,1H),8.58(d,J＝8.3,1H),8.16(s,1H),7.99(s,1H),7.92(dd,J＝8.0,1.4,1H),7.77–7.69(m,1H),7.66–7.59(m,1H),7.58(s,1H),7.56–7.52(m,1H),7.49(t,J＝5.4,1H),7.25(d,J＝8.0,1H),7.19(d,J＝8.4,1H),6.75(s,1H),5.07–4.92(m,1H),4.67–4.59(m,2H),4.60–4.47(m,1H),3.51–3.11(m,7H),2.97–2.67(m,6H),2.48(t,J＝6.0,2H),2.28(dd,J＝22.1,11.6,2H),2.18(d,J＝21.2,4H),1.90–1.67(m,4H),1.55(ddd,J＝26.9,13.5,6.7,5H),1.34(dd,J＝15.3,6.5,12H).13C NMR(101MHz,CDCl3)δ＝172.42,171.67,171.13,168.61,166.71,166.67,166.10,157.47,155.34,155.29,154.50,144.80,138.48,137.01,134.64,133.59,131.26,127.84,127.15,124.86,123.61,123.12,120.95,119.65,118.21,117.35,110.97,105.82,71.73,68.10,60.38,55.48,54.20,53.82,49.36,39.11,38.97,37.67,32.40,32.15,31.52,29.54,29.05,26.69,26.39,22.71,22.23,21.04,18.91,15.36,14.20.HRMS(DART-TOF)calculated forC52H65ClN9O10S[M+H]+m/z 1042.4264,found 1042.4293.
目标产物G3的合成：
Figure BDA0001722582780000421
该目标产物制备方法同G1，原料为G3-M，其它原料和处理方法相同，产率为21％。
1H NMR(400MHz,CDCl3)δ＝9.52(s,1H),8.58(d,J＝8.2,1H),8.16(s,1H),7.99(s,1H),7.93(dd,J＝8.0,1.5,1H),7.73(dd,J＝10.1,5.7,1H),7.62(dd,J＝10.4,3.2,2H),7.55(t,J＝6.0,1H),7.39(t,J＝5.6,1H),7.26–7.23(m,1H),7.19(d,J＝8.4,1H),6.75(s,1H),4.96(dd,J＝12.3,5.3,1H),4.63(t,J＝7.8,2H),4.59–4.45(m,1H),3.29(dddd,J＝27.1,23.9,16.5,8.6,7H),2.98–2.67(m,6H),2.49(d,J＝5.7,2H),2.23(d,J＝21.1,2H),2.20–2.13(m,3H),1.89–1.69(m,4H),1.62–1.49(m,4H),1.44–1.29(m,18H).13C NMR(101MHz,CDCl3)δ＝171.39,168.35,166.68,166.61,166.01,157.46,155.37,155.27,154.49,144.86,138.48,137.03,134.63,133.61,131.28,124.91,123.63,123.13,120.94,119.49,118.13,117.33,110.93,105.87,71.71,68.00,55.48,53.85,49.39,39.09,31.58,29.70,29.35,29.12,29.01,26.78,26.62,22.59,22.21,18.93,15.37.HRMS(DART-TOF)calculated for C54H69ClN9O10S[M+H]+m/z 1070.4577,found 1070.4604.
9、H系列PROTAC分子的结构与合成
Figure BDA0001722582780000422
中间体H1-M的合成：
Figure BDA0001722582780000423
该中间体的制备方法同G1-M，原料为[2-(2-氨基乙氧基)乙基]氨基甲酸叔丁酯，其他原料和处理方法相同。产率为62％。
1H NMR(400MHz,CDCl3)δ＝7.78–7.71(m,1H),7.52(t,J＝9.6,1H),7.21(t,J＝8.5,1H),4.71–4.60(m,2H),3.71–3.47(m,6H),3.35(s,2H),2.98–2.67(m,3H),2.26–2.08(m,1H),1.51–1.31(m,9H).HRMS(DART-TOF)calculated for C24H30N4O9Na[M+Na]+m/z541.1910,found 541.1933.
中间体H2-M的合成：
Figure BDA0001722582780000431
该中间体的制备方法同G1-M，原料为2-(2-(2-氨基乙氧基)乙氧基)乙基氨基甲酸叔丁酯，其他原料和处理方法相同。产率为51％。
1H NMR(400MHz,CDCl3)δ＝7.74(dd,J＝8.3,7.5,1H),7.54(d,J＝7.2,1H),7.21(d,J＝8.4,1H),5.06–4.95(m,1H),4.69(d,J＝17.6,2H),3.74–3.48(m,10H),3.32(dd,J＝28.2,4.0,2H),2.96–2.71(m,3H),2.23–2.09(m,1H),1.40(d,J＝21.6,9H).HRMS(DART-TOF)calculated for C26H34N4O10Na[M+Na]+m/z 585.2173,found 585.2199.
中间体H3-M的合成：
Figure BDA0001722582780000432
该中间体的制备方法同G1-M，原料为13-氨基-5,8,11-三氧杂-2-氮杂十三烷酸1,1-二甲基乙酯，其他原料和处理方法相同。产率为41％。
1H NMR(400MHz,CDCl3)δ＝7.78–7.70(m,1H),7.54(d,J＝7.3,1H),7.20(d,J＝8.4,1H),4.98(dd,J＝12.0,5.4,1H),4.66(s,2H),3.84–3.50(m,15H),3.30(s,2H),2.99–2.69(m,3H),2.22–2.11(m,1H),1.43(s,9H).HRMS(DART-TOF)calculated forC28H38N4O11Na[M+Na]+m/z 629.2435,found 629.2440
目标产物H1的合成：
该目标产物的制备方法同G1，原料为H1-M，其他原料和处理方法相同。产率为23％。
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.58(d,J＝8.1,1H),8.15(d,J＝4.4,1H),7.99(s,1H),7.92(dd,J＝8.0,1.5,1H),7.76–7.71(m,1H),7.67(d,J＝4.9,1H),7.64–7.59(m,1H),7.58–7.50(m,3H),7.25(dd,J＝9.5,2.3,1H),7.22–7.16(m,1H),5.05–4.92(m,1H),4.63(s,2H),4.54(dt,J＝12.1,6.0,1H),3.68–3.42(m,9H),3.33–3.13(m,4H),2.91–2.62(m,7H),2.50(s,2H),2.14(s,3H),1.79(s,4H),1.37–1.29(m,14H).13C NMR(101MHz,CDCl3)δ＝171.67,171.12,168.96,166.71,166.67,166.15,157.48,155.32,154.28,144.77,138.49,137.02,134.65,133.66,131.25,127.78,127.08,124.86,123.63,123.11,120.82,119.16,117.97,117.25,111.07,105.78,71.75,69.58,69.37,67.64,60.38,55.47,54.09,53.95,53.84,49.39,39.37,38.83,37.73,32.72,32.05,31.52,29.68,22.91,22.24,21.04,18.92,15.37,14.20.HRMS(DART-TOF)calculated for C50H61ClN9O11S[M+H]+m/z 1030.3900,found 1030.3875.
目标产物H2的合成：
Figure BDA0001722582780000442
该目标产物的制备方法同G1，原料为H2-M，其他原料和处理方法相同。产率为26％。
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.58(d,J＝8.0,1H),8.21–8.09(m,1H),7.98(s,1H),7.92(dd,J＝8.0,1.5,1H),7.73(dd,J＝8.3,7.5,1H),7.65–7.59(m,2H),7.58(s,1H),7.53(d,J＝7.2,1H),7.27(d,J＝9.8,1H),7.19(d,J＝8.4,1H),6.79(s,1H),5.04–4.93(m,1H),4.66(d,J＝14.3,2H),4.60–4.51(m,1H),3.73–3.52(m,10H),3.45(dd,J＝10.7,5.3,2H),3.27(dq,J＝13.7,6.8,1H),3.16(d,J＝10.6,2H),2.92–2.63(m,6H),2.49(s,2H),2.18–2.12(m,4H),1.79(s,3H),1.38–1.28(m,12H).13C NMR(101MHz,CDCl3)δ＝171.63,171.12,168.67,166.89,166.66,165.92,157.49,155.33,155.29,154.43,144.81,138.49,136.98,134.65,133.68,131.25,127.72,127.03,124.84,123.62,123.10,120.86,119.38,118.03,117.29,111.12,105.76,71.67,70.33,69.92,69.53,67.95,60.38,55.47,54.13,53.94,49.35,39.05,39.00,37.84,32.75,32.34,31.52,22.71,22.23,21.04,18.93,15.36,14.20.HRMS(DART-TOF)calculated for C52H65ClN9O12S[M+H]+m/z1074.4162,found 1074.4153.
目标产物H3的合成：
Figure BDA0001722582780000451
该目标产物的制备方法同G1，原料为H3-M，其他原料和处理方法相同。产率为25％。
1H NMR(400MHz,CDCl3)δ＝9.44(s,1H),8.51(d,J＝8.3,1H),8.09(d,J＝1.3,1H),7.91(s,1H),7.85(dd,J＝7.9,1.5,1H),7.72(d,J＝4.9,1H),7.65(dd,J＝10.7,5.0,1H),7.59(s,1H),7.57–7.53(m,1H),7.52(s,1H),7.45(dd,J＝7.3,2.0,1H),7.20–7.15(m,1H),7.15–7.08(m,1H),6.76–6.66(m,1H),4.90(dd,J＝11.9,5.4,1H),4.57(s,2H),4.47(dt,J＝12.1,6.1,1H),3.78–3.44(m,16H),3.38(s,2H),3.09(d,J＝10.3,2H),2.90–2.54(m,7H),2.08(s,4H),1.25(dd,J＝10.5,6.5,13H).13C NMR(101MHz,CDCl3)δ＝172.37,171.76,168.78,166.92,166.64,165.91,157.46,155.31,155.28,154.43,144.78,138.45,137.03,134.69,133.62,131.25,127.66,127.04,124.78,123.61,123.13,120.86,119.42,117.99,117.27,111.02,105.73,71.60,70.32,70.20,69.93,69.43,67.89,60.40,55.45,54.29,53.94,49.28,39.06,38.95,37.76,32.62,32.32,31.45,29.69,22.73,22.22,21.07,18.96.HRMS(DART-TOF)calculated for C54H69ClN9O13S[M+H]+m/z 1118.4424,found1118.4403.
对比化合物L10A的合成：
中间体L10的合成：
Figure BDA0001722582780000452
以癸二酸为原料(202mg，1mmol)，溶于20mLDMF中，加入HATU(1140mg,3mmol)，DIPEA(774mg,6mmol),LDK378(279mg,0.5mmol)常温搅拌10h。TLC监测反应进展，反应完成后，用30mL水淬灭反应，用EA萃取水层后，合并有机层，用饱和食盐水反洗后用无水硫酸钠干燥，减压浓缩后，用DCM/MeOH作为流动相进行柱层析分离。得白色固体，产率约为53％。
1H NMR(400MHz,CDCl3)δ＝9.54(s,1H),8.57(d,J＝8.3,1H),8.14(s,1H),8.00–7.88(m,2H),7.75(s,1H),7.66–7.54(m,1H),7.29–7.25(m,1H),6.69(s,1H),4.83(d,J＝12.9,1H),3.36–3.09(m,2H),2.34(ddd,J＝20.8,15.2,7.6,7H),2.18(s,3H),1.74–1.50(m,10H),1.39–1.28(m,25H).13C NMR(101MHz,CDCl3)δ＝178.57,174.34,172.00,157.37,155.45,154.82,145.15,138.39,136.96,134.62,131.27,127.72,126.81,124.93,123.68,123.20,121.31,110.97,105.71,71.65,55.52,51.46,46.64,42.68,38.62,38.35,34.12,34.07,33.44,32.28,29.68,29.42,29.31,29.16,29.07,29.02,25.39,24.89,24.74,22.22,22.14,18.95,15.35.HRMS(DART-TOF)calculated for C38H53ClN5O6S[M+H]+m/z742.3405,found 742.3401.
Figure BDA0001722582780000461
称取L10(137mg，0.2mmol)，溶于10mLDMF中，加入HATU(91mg,0.24mmol)，DIPEA(73mg,0.6mmol),(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrro lidine-2-carboxamide(86mg,0.2mmol)常温搅拌15h。TLC监测反应进展，反应完成后，用30mL水淬灭反应，用EA萃取水层后，合并有机层，用饱和食盐水反洗后用无水硫酸钠干燥，减压浓缩后，用DCM/MeOH作为流动相进行柱层析分离。得白色固体，产率约为19％。
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.68(s,1H),8.58(d,J＝8.4,1H),8.15(s,1H),8.02(s,1H),7.93(dd,J＝7.9,1.4,1H),7.62(t,J＝7.2,1H),7.56(s,1H),7.35(q,J＝8.5,5H),6.68(s,1H),6.17(d,J＝8.7,1H),4.88–4.69(m,3H),4.65–4.49(m,5H),4.36(d,J＝4.6,1H),3.61(dd,J＝11.3,3.4,1H),3.30–3.22(m,1H),2.51(s,4H),2.42–2.32(m,3H),2.24–2.13(m,7H),2.04(s,1H),1.70–1.50(m,10H),1.40–1.25(m,34H),0.94(s,11H).13CNMR(101MHz,CDCl3)δ＝173.87,172.03,171.70,170.70,157.45,155.36,150.31,148.47,144.78,138.50,138.12,136.64,134.61,131.30,130.98,129.54,128.14,127.90,126.91,124.95,123.64,123.12,120.79,71.68,70.06,58.44,57.48,56.73,55.48,43.28,42.57,38.37,36.41,35.90,34.84,33.46,29.70,29.29,29.17,28.99,26.42,25.46,25.37,22.29,22.21,18.97,16.04,15.37.HRMS(DART-TOF)calculated for C60H81ClN9O8S2[M+H]+m/z 1154.5338,found 1154.5331.
对比化合物L11A的合成：
中间体L11的合成：
Figure BDA0001722582780000471
中间体L11的合成步骤参照L10，但将原料换为十一烷二酸，产率约为48％
1H NMR(400MHz,CDCl3)δ＝9.55(s,1H),8.56(d,J＝8.3,1H),8.15(s,1H),8.00–7.88(m,2H),7.72(d,J＝4.0,1H),7.65–7.55(m,1H),7.24(s,1H),6.67(d,J＝16.2,1H),4.63–4.48(m,1H),4.00(d,J＝13.1,1H),3.34–3.09(m,2H),2.62(dd,J＝23.1,10.4,1H),2.47–2.26(m,4H),2.20(d,J＝21.4,3H),1.84(dd,J＝27.8,15.0,3H),1.71–1.53(m,6H),1.33(dt,J＝25.6,12.0,25H).13C NMR(101MHz,CDCl3)δ＝178.54,175.99,172.08,157.34,155.47,154.83,145.11,138.39,136.92,134.61,131.29,127.73,126.82,124.99,123.69,123.22,121.22,110.95,105.78,71.68,55.52,46.67,42.70,38.63,38.35,34.01,33.51,32.28,29.70,29.53,29.42,29.24,29.15,29.07,28.97,25.42,24.69,22.24,22.16,20.76,18.95,15.36.HRMS(DART-TOF)calculated for C39H55ClN5O6S[M+H]+m/z 756.3562,found 756.3561.
Figure BDA0001722582780000472
该化合物的合成步骤参照L10A，但将原料换为L11，产率约为22％。
1H NMR(400MHz,CDCl3)δ＝9.51(s,1H),8.67(s,1H),8.58(d,J＝8.3,1H),8.16(s,1H),8.03(s,1H),7.93(dd,J＝8.0,1.5,1H),7.66–7.58(m,1H),7.55(s,1H),7.39–7.31(m,5H),7.24(s,1H),6.68(d,J＝2.8,1H),4.76(t,J＝8.1,2H),4.63–4.46(m,4H),4.34(dd,J＝14.9,4.6,1H),4.11(d,J＝11.2,1H),3.96(d,J＝13.4,1H),3.60(dd,J＝11.3,3.4,1H),3.26(dt,J＝13.6,6.8,1H),2.66–2.49(m,5H),2.36(d,J＝6.8,2H),2.17(s,4H),1.80(t,J＝14.0,2H),1.74–1.46(m,8H),1.40–1.28(m,13H),0.92(d,J＝20.4,10H).13C NMR(101MHz,CDCl3)δ＝173.56,172.13,171.13,170.71,157.45,155.35,150.30,148.49,144.74,138.50,138.12,136.51,134.61,131.59,131.30,131.00,129.54,128.15,127.94,126.91,124.95,123.63,123.12,120.75,110.86,105.91,71.69,70.11,58.41,57.77,56.87,55.48,46.43,43.27,42.68,38.33,35.97,34.86,33.38,32.80,32.26,26.44,25.46,24.34,22.29,18.97,16.05,15.37.HRMS(DART-TOF)calculated for C60H81ClN9O8S2[M+H]+m/z 1168.5495,found 1168.5491.
试验例1对ALK的激酶活性测试
化合物浓度梯度的配制：受试化合物测试浓度为200nM和20nM，在96孔板中稀释成100倍终浓度的100％DMSO溶液,然后用1×Kinase buffer将各浓度的化合物进一步稀释成5倍终浓度的中间稀释溶液。化合物测试浓度为200nM起始,5倍稀释10个浓度，单孔测试，同样在96孔板中稀释成100倍终浓度10个浓度梯度的100％DMSO溶液，然后用1×Kinasebuffer将各浓度的化合物进一步稀释成5倍终浓度的中间稀释溶液。
将配制好的化合物溶液各取5μL分别加入384孔板的化合物孔，每个浓度单孔测试；阴性对照孔和阳性对照孔中分别加5μL的5％DMSO。
用1×Kinase buffer配制2.5倍终浓度的激酶溶液。
在化合物孔和阳性对照孔分别加10μL的2.5倍终浓度的激酶溶液；在阴性对照孔中加10μL的1×Kinase buffer。
1000rpm离心30秒，振荡混匀后室温孵育10分钟。
用1×Kinase buffer配制2.5倍终浓度的ATP和Kinase substrate22的混合溶液。
加入10μL的2.5倍终浓度的ATP和底物的混合溶液，起始反应。
将384孔板1000rpm离心30秒，振荡混匀后28度孵育25分钟。
加入25μL终止检测液停止激酶反应，1000rpm离心30秒，振荡混匀
用Caliper EZ ReaderⅡ读取转化率。
数据分析：
计算公式％Inhibition＝(Conversion％_max-Conversion％_sample)/(Conversion％_max-Conversion％_min)×100％
其中：Conversion％_sample是样品的转化率读数；Conversion％_min：阴性对照孔均值，代表没有酶活孔的转化率读数；Conversion％_max：阳性对照孔比值均值，代表没有化合物抑制孔的转化率读数。
计算结果见表1。
表1化合物分子在200nM和20nM下对ALK的抑制率(％)
编号 抑制率(200nM) 抑制率(20nM) 编号 抑制率(200nM) 抑制率(20nM)
L4P 95.3 19.1 C2 95.2 2.3
L6P 99.8 47.2 C3 96.6 81.4
L7P 94 20.4 D1 99.5 93.9
L12P 99.3 98.2 D2 97.6 94.8
A1 96.8 56.9 D3 101.4 94.9
A2 97.9 73.2 E1 100.6 99.7
A3 94.5 53.8 E2 101.1 80.4
A4 93.8 35.6 E3 99.8 72.6
A5 97.3 92.7 F1 100.9 100.7
A6 93.6 91.5 F2 98.3 99.2
A7 98.6 57.9 G1 100.7 64.9
B1 101.1 87.7 G2 98.9 98.4
B2 99.6 97.2 G3 100.3 91.8
B3 100.8 98.4 H1 100.5 97.6
B4 100.6 79.1 H2 99.7 100.3
B5 99.6 91.3 H3 99.3 100.5
B6 99.1 85.1 LDK378 99.8 99.6
B7 99.3 81.2 L10A 64.4 27.2
C1 99.2 89.1 L11A 71.4 7.2
从表1可以看出，本发明化合物对ALK的抑制率与阳性药LDK378相当，可见，接入本发明的特定的E3连接酶配体不会在很大程度上影响药物分子对ALK的激酶活性，而接入其他配体，比如接入VHL抑制剂类的PROTAC分子，将会造成对ALK的抑制活性急剧下降。
测定B3对ALK抑制率与浓度的关系，其结果见表2，根据表2数据，以浓度的log值作为X轴，百分比抑制率为Y轴，采用分析软件GraphPad Prism 5的log(inhibitor)vs.response-Variable slope拟合量效曲线，从而得出B3化合物对酶活性的IC50值为0.7nM。
表2
B3浓度(nM) Log con. ％inhibition
200 2.301029996 99.2
40 1.602059991 101.3
8 0.903089987 98.2
1.6 0.204119983 72.1
0.32 -0.494850022 28.5
0.064 -1.193820026 6.0
0.0128 -1.89279003 -1.3
0.00256 -2.591760035 9.8
0.000512 -3.290730039 -4.4
0.0001024 -3.989700043 -7.4
试验例2对肿瘤细胞的抑制活性
采用MTT法测定本发明的化合物在体外对肿瘤细胞的抑制活性，本实验所用的细胞株包括：H3122(人类非小细胞肺癌细胞株)，H2228(人类非小细胞肺癌细胞株),H1299(人肺癌细胞),A549(人肺癌细胞)，Hela(人宫颈癌细胞)。
实验方法为：
取对数生长期肿瘤细胞，用胰酶消化，离心并用新鲜培养基重悬，将细胞按照合适的密度接种于96孔板中，每孔培养基100μL。将接种好后，将96孔板置于孵箱中继续培养24h，使肿瘤细胞贴壁。培养环境：温度37℃，5％CO2。待细胞贴壁并达到合适细胞密度时，加药，初筛的浓度设置为20、10、5μM，精筛的浓度设计为10、5、2.5、1.25、0.625、0.3μM。72h后停止实验，加入20μL MTT溶液(5mg/mL)，放入细胞培养箱中作用4h。取出孔板，弃上清液，每孔再加入150μL DMSO以溶解甲瓒。待结晶充分溶解后，使用酶标仪测定每孔在490和570nm的吸光度值(OD值)，计算各个实验组中肿瘤细胞体外增殖抑制率和细胞存活率。根据公式：相对细胞增殖抑制率(％)＝(空白对照组-实验组)/空白对照组×100％。每组设置3个平行复孔，每个实验重复三次。实验结果见表3。
表3：化合物的体外抗肿瘤活性(IC50：μM)
编号 H3122 H2228 H1299 A549 HeLa
L12P ＞20 ＞20 ＞20 7.54 7.98
B1 ＞20 ＞20 ＞20 5 4.57
B2 0.7 3.5 7.59 2.6 2.23
B3 0.3 0.9 2.84 1.6 1.18
B4 8.37 ＞20 ＞20 ＞20 ＞20
C1 3.52 8.7 ＞20 13.38 8.15
C2 1.1 3.1 ＞20 5.13 4.36
C3 2.66 15.1 ＞20 ＞20 7.67
D1 1.83 5.74 7.23 6.73 5.78
D2 2.34 4.51 10.86 5.81 5.86
D3 ＞20 ＞20 ＞20 ＞20 12.21
E1 ＞20 7.6 ＞20 14.34 9.05
F1 4.86 5.2 12.28 20.9 7.98
F2 ＞20 5.7 14.9 6.01 5.52
G1 1.3 ＞20 9.33 ＞20 6.99
G2 ＞20 ＞20 18.83 4.66 3.87
H1 5.41 12.9 10.16 ＞20 7.94
LDK378 1.1 1.3 2.92 1.32 0.94
L10A ＞20 ＞20 ＞20 ＞20 ＞20
L11A ＞20 ＞20 ＞20 ＞20 ＞20
从表3可以看出，本发明的化合物采用不同的linker进行偶联，有多个分子具有体外抗肿瘤活性。其中，化合物B2和B3对H3122的抑制活性超过了阳性药LDK378。而大部分的化合物的体外抗肿瘤活性均超过了对比化合物L10A和L11A，可见，本发明采用泊马度胺类的E3连接酶配体，其体外抗肿瘤活性大于采用VHL抑制剂类的PROTAC分子，VHL抑制剂类的PROTAC分子未能在细胞层面上抑制ALK活性或有效降解ALK而起到抑制细胞增殖的作用。
试验例3对正常细胞的毒性试验研究
采用MTT法，测定了部分抗肿瘤活性较好的化合物分子对LO2(人正常肝细胞系)在5μm给药浓度下的细胞毒性。其结果见表4。
表4
编号 抑制率 编号 抑制率
B2 33.57％ D1 32.36％
B3 63.22％ D2 52.78％
C1 29.77％ F2 65.48％
C2 54.47％ G2 59.43％
C3 43.55％ LDK378 68.47％
实验结果表明，在同等浓度下，PROTAC分子对LO2的抑制率均低于阳性药LDK378。说明了PROTAC分子具有一定的选择性，安全性也较好。
试验例4B3分子蛋白质印迹
采用WB的方法，对PROTAC分子处理过的细胞中ALK及相关蛋白的量进行考察。
实验方法：
细胞处理和收集：本实验在6孔板中进行。取对数生长期细胞，用胰酶消化，离心并用新鲜培养基重悬，将细胞按照合适的密度接种于6孔板中，每孔培养基体积1mL。细胞贴壁后按一定的浓度梯度加入B3分子或阳性药LDK378，处理12h后收集细胞，用预冷的PBS洗2次，然后在转速1200rpm下离心3min，弃上清液；再次离心，弃上清液。
细胞裂解：将6孔板置于冰上，加入适当体积的RIPA裂解液，作用30min。RIPA裂解液中含有1％的Cocktail蛋白酶抑制剂以及1％的磷酸化酶抑制剂。之后用细胞超声破碎仪将细胞裂解液置于冰上超声3次，每次3秒，间隙2秒。超声功率：35％，温度控制：20℃。将细胞裂解液置于4℃离心机中离心15min，转速13300rpm。收集上清，用NANODROP 2000仪器测定每组样品的蛋白浓度。然后使用RIPA裂解液将蛋白浓度调整至适宜的浓度，加入蛋白上样缓冲液，沸水煮样品5-10min。离心1min，转速133000rpm，将样品置于－20℃冰箱中冷冻保存。
SDS-PAGE凝胶电泳操作：
根据实验需要，我们使用8-15％的聚丙烯酰胺凝胶分离蛋白。
上样：将配置好的胶板安装于电泳槽中，加入电泳缓冲液。使用移液枪将蛋白Marker和样品分别加入到上样孔中。
电泳：连接电源，将电压调至80V，恒压跑SDS-PAGE凝胶电泳，直至样品跑到浓缩胶和分离胶的分界线处，且蛋白Marker条带略微分开。将电压提高至120V，恒压跑SDS-PAGE凝胶电泳。直至蛋白预染Marker到达所需位置，终止电泳。取出凝胶并开始转膜。
转膜：
取出加在玻璃板内的凝胶，按照实验所需蛋白位置截取合适的凝胶，将其放置于转膜缓冲液中。
剪出合适大小的PVDF膜，按照顺序装配转膜“三明治”装置，即海绵—3-4层滤纸—凝胶—PVDF膜—3-4层滤纸—海绵，将每层按顺序放好后，夹紧装置，安装于转移槽中，加满转膜缓冲液。
将装置置于冰浴中，接通电源开始转膜。恒压100V；转膜时间45min。
转膜结束后，取出PVDF膜，放于TBS缓冲液中。
免疫杂交和显色：
1)1×TBS洗膜2次，每次5min，室温摇床缓慢摇动。
2)将PVDF膜置于封闭缓冲液中，室温摇床缓慢摇动，封闭2h。
3)用1×TBS/T缓冲液洗膜3次，每次5min。
4)将PVDF膜置于杂交袋中，加入合适浓度的一抗。4℃摇床缓慢摇动，孵育一抗过夜。
5)次日，取出孵育过一抗的PVDF膜，1×TBS/T洗膜3次，每次5min。
6)将膜置于含相应二抗的杂交袋中，37℃置于摇床孵育1h，使用TBS/T缓冲液洗膜3次，每次15min，最后再用TBS缓冲液洗膜一次，时间为5min。
7)显影：按照发光法进行显影。发光反应时将试剂盒中两种溶液按1:1比例混合，将PVDF膜浸没于溶液中，静置一段时间，上机检测。最后对条带进行分析，使用GAPDH作内参。
实验结果见图1。
根据WB结果发现，PROTAC分子能够有效降解细胞内部的ALK，且化合物分子对于ALK的降解能力呈现浓度相关性。证明了这些分子可以在细胞内实现诱导降解ALK蛋白。通过影响ALK蛋白的含量，细胞内p-S6的含量也出现了降低。
试验例5 PI/Annexin V双染检测凋亡
磷脂酰丝氨酸是一种带负电荷的磷脂结构，正常情况下主要存在于细胞膜的内侧面，在细胞发生凋亡的时候，磷脂酰丝氨酸会转移到细胞膜外。Annexin V是一种钙离子依赖性磷脂结合蛋白，能与膜外磷脂酰丝氨酸高亲和力特异性结合。但PS转移到细胞膜外这一现象也可发生在细胞坏死中。这两种细胞死亡方式间的差别是在凋亡的初始阶段细胞膜是否完好，坏死细胞在其早期阶段细胞膜的完整性就被破坏了。Propidium iodide(PI)是一种核酸染料，它不能透过完整的细胞膜，但在凋亡中晚期的细胞和死细胞，PI能够透过细胞膜与细胞核结合呈现红色。所以将Annexin V与PI匹配使用，可以将凋亡早期的细胞和晚期的细胞以及死细胞区分开来。
实验器材：预冷PBS缓冲液，0.25％不含EDTA胰酶，离心机，Annexin V/PI双染试剂盒，流式细胞仪。
细胞收集：取对数生长期的H3122细胞，用0.25％不含EDTA的胰酶消化并用吸管吹打成单个细胞悬浮细胞直接收集到10mL的离心管中，每样本细胞数为(1-5)×106个/mL，1500r/min离心5min，弃去培养液。之后，用预冷的PBS缓冲液洗涤2次，1500r/min离心5min，弃上清液。
染色：根据Annexin V/PI双染试剂盒说明书，加入195μL的结合液重悬细胞，混匀；加入5μL的Annexin V-FITC混匀后，避光，室温孵育15分钟，再加入5μL的PI染色5-15分钟后，上机检测。
流式细胞仪分析：流式细胞仪激发光采用488nm波长段，用一波长为515nm的通带滤器来检测FITC荧光，另一波长大于560nm的滤器检测来PI。
试验结果见图2。
从图2可以看出，在双变量的散点图上，左下象限为双阴结果(FITC-/PI-)，代表活细胞；右上象限为双阳结果为(FITC+/PI+)表示坏死细胞或晚期凋亡细胞；而右下象限为FITC阳性，PI阴性，代表早期凋亡的细胞。从图中我们可以明显看出：H3122细胞的凋亡率随着目标化合物B3浓度的增加而逐步增加，在20μM浓度时，早期凋亡率达到34.9％，故可推测目标化合物B3能诱发非小细胞肺癌株H3122发生凋亡，并具有浓度依数性。
试验例6分子荧光特性测试
采用了荧光酶标仪测定本发明分子的吸收波长和激发波长。具体测定方法如下：
使用荧光酶标仪进行波长扫描，将B3溶解于二甲亚砜中，量取100微升置于96孔板，设定的吸收波长扫描范围为300-700nm，得到一个B3分子的吸收谱图，详见图3。
从化合物分子的吸收谱图情况，可以看出该化合物在390-450nm波长均有较强的紫外吸收，最大的吸收波长为420nm。因此，以420nm波长作为激发波长，发射波长的扫描范围为450nm-700nm波长。结果如图4。
从图4可以发现，B3分子在520nm波长下有最强的荧光强度。综上所述，化合物B3的激发波长为420nm，发射波长为520nm。
根据该化合物分子的荧光特性，观察化合物分子在细胞内或动物体内的分布，在6孔板中接种合适密度的H2228细胞，待细胞贴壁后，按顺序加入20μm,10μm，5μm，2.5μm，1.25μm的B3及等量DMSO。培养48h后，将6孔板置于荧光倒置显微镜下观察，六孔板中A-F的六个孔对应的B3的浓度为20μm,10μm，5μm，2.5μm，1.25μm的B3及等量DMSO。在紫光下观察(4倍镜头)，蓝色荧光的强度明显随浓度的下降而减弱，而视野中细胞的密度随药物浓度的降低而增大。
化合物B3分子在细胞内的分布见图5。在放大倍数为20倍时，用紫光可以明显看到化合物在细胞内富集，且浓度远大于胞外的培养基，图5为放大倍数40倍时，紫光与白光下效果的叠合图，可以明显观察到，荧光区域主要集中在细胞内的胞浆区域，说明B3主要分布在细胞质中。
通过研究发现，B3分子的荧光区域也是一个平面区域，可能由于分子间π-π作用使分子荧光减弱，在细胞内或细胞外与ALK蛋白结合后，分子间的π-π作用减弱，可以使与蛋白结合的分子荧光强于游离状态，从而标记ALK蛋白的位置。ALK蛋白作为一个致癌蛋白，不同细胞内该蛋白含量不同，根据加药后细胞内荧光强度的不同，可以判断胞内ALK蛋白含量。
为了判断分子细胞活性与ALK蛋白含量的关系，在三个培养皿中培养了等量的细胞，分别为LO2，H1299，H3122，分别加入1.25μM的B3，用荧光倒置显微镜观察细胞内荧光的强弱，其结果如图6所示。可见，蛋白的含量与分子对细胞的活性是一致的，说明该分子可以用于分子示踪，也可以标记细胞内ALK蛋白的含量。
试验例7 B3分子体内抗肿瘤活性研究
为了研究PROTAC分子在动物体内的抗肿瘤活性，我们对化合物分子B3进行了体内抗肿瘤活性研究，选用的细胞株为H3122，实验动物为Balb/c nude小鼠。
实验动物：
所用小鼠购于北京华阜康生物科技股份有限公司，饲养于四川大学生物治疗国家重点实验室动物房(SPF级)。小鼠为SPF级，按照NationalInstitutes of Health Guidefor the Care and Use of Laboratory Animals标准饲养。实验动物的使用由四川大学伦理委员会(Institutional Ethics Committee of Sichuan University)审议批准。实验动物饲养条件：温度16-26℃，相对湿度40％-70％，采用人工照明系统，12h明暗交替，Co60灭菌饲料(北京科澳协力饲料有限公司)，自由饮水。
移植肿瘤动物模型建立：
移植性肿瘤动物模型分为同种移植和异种移植，是将动物或人源肿瘤移植到同种或异种动物体内增殖而形成肿瘤。异种动物移植常将肿瘤细胞接种于裸鼠皮下，该方法成瘤率高，成瘤时间均一，瘤体大小和肿瘤重量易于检测。
在本课题中，我们建立移植性H3122肿瘤小鼠动物模型，旨在评价化合物B3的体内抗肿瘤效果。具体方法如下：
1)胰酶消化对数生长期的H3122肿瘤细胞后，离心收集细胞；用双无(无抗生素无血清)培养基清洗细胞3次；加入适量双无培养基重悬肿瘤细胞，并对肿瘤细胞进行密度测定；根据实验要求将细胞密度调至5×106个/mL。
2)将重悬好的细胞按照每只小鼠0.5×106个细胞(0.1mL)将细胞接种到小鼠(6-8周龄，体重18-22g)的右腋部皮下。
3)接种后10天左右，小鼠接种部位肿瘤成瘤，体积150-200mm3时，将所有肿瘤体积相近的小鼠随机分组。实验设置2组：控制组和给药组(B3 10mg/kg,20mg/kg,40mg/kg,100mg/kg；阳性对照LDK378 20mg/kg)，每组7只。药物溶媒采用PEG300:NMP＝9的混合溶媒,每只裸鼠每天平均口服给药0.2mL。
实验数据记录：每3天测量一次肿瘤体积和小鼠体重，包括肿瘤长径和垂直于长径的短径，单位：毫米(mm)；小鼠体重，单位:克(g)。实验期间需要注意观察小鼠健康状况，如动物活动情况、进水进食情况、小鼠毛发光泽度及颜色、有无腹泻和肿瘤部位有无炎症等。
瘤体积(mm3)＝肿瘤长径×短径×短径/2
抑瘤率(％)＝(对照组肿瘤平均体积－实验组肿瘤平均体积)/对照组肿瘤平均体积×100％。
实验进行15天。实验结束后，使用水合氯醛麻醉处死小鼠，取出小鼠心、肝、脾、肺和肾等脏器，同时，剥离肿瘤组织。将主要脏器和肿瘤组织按分组用4％多聚甲醛固定。肿瘤体积随给药时间的变体见图7，裸鼠体重随给药日期的变化见图8。
试验结果表明，实验期间小鼠健康状况良好：活动情况正常、进水进食情况正常、小鼠皮肤光泽度及颜色正常、无腹泻现象发生，肿瘤部位无炎症出现。从给药结果来看，化合物B3与控制组组相比能够抑制肿瘤组织增长，化合物B3与控制组相比能够抑制肿瘤组织增长，在给药剂量为10mg/kg,20mg/kg,40mg/kg,100mg/kg时抑瘤率为45.5％，59.1％，61.2％，70.1％；与之相比，阳性药LDK378在给药剂量为20mg/kg时的抑瘤率为49.5％，同等给药剂量下，B3的体内抗肿瘤活性优于阳性药物LDK378。小鼠体重在给药期间比较平稳，各给药组之间差异并不明显。

Claims (12)

1.结构式如式Ⅰ所示的化合物：
其中，L为连接体基团。
2.根据权利要求1所述的化合物，其特征在于：L为其中，*端连接色瑞替尼哌啶环中的N，Z为-CH2-、
Figure FDA0001722582770000013
Figure FDA0001722582770000014
Z1为-CH2-、-NH-、-O-、-S-、
Figure FDA0001722582770000015
Z2为-CH2-、-NH-、-O-或-S-，m0为0～15中任一整数，m为0～15中任一整数，m1为0～8中任一整数，m2为0～8中任一整数，m3为0～8中任一整数，m4为0～15中任一整数，m5为0～15中任一整数；n为1～3中任一整数；M为H或1～8的饱和烷烃或环烷烃。
3.根据权利要求2所述的化合物，其特征在于：Z为
Figure FDA0001722582770000017
Z1为-NH-、
Figure FDA0001722582770000018
Z2为-CH2-或-O-。
4.根据权利要求2或3所述的化合物，其特征在于：m0为1或2。
5.根据权利要求3或4所述的化合物，其特征在于：Z为
Figure FDA0001722582770000021
6.根据权利要求2～5任一项所述的化合物，其特征在于：Z1为-NH-、
Figure FDA0001722582770000022
Figure FDA0001722582770000023
7.根据权利要求2～6任一项所述的化合物，其特征在于：Z2为-O-，m1为1，m2为1。
8.根据权利要求1所述的化合物，其特征在于：其结构式如B2、B3、C2、D1或G1所示：
Figure FDA0001722582770000024
9.权利要求1～8任一项所述的化合物在制备治疗肿瘤药物中的应用。
10.根据权利要求7所述的化合物在制备治疗肿瘤药物中的应用，其特征在于：所述肿瘤为肺癌或宫颈癌。
11.用于治疗肿瘤的药物组合物，其特征在于：含有治疗有效量的权利要求1～6任一项所述的化合物和药学上可接受的载体。
12.权利要求1～8任一项所述的化合物在制备荧光示踪剂或肿瘤标志物中的应用。
CN201810738298.4A 2018-07-06 2018-07-06 靶向alk的protac及其应用 Pending CN110684015A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810738298.4A CN110684015A (zh) 2018-07-06 2018-07-06 靶向alk的protac及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810738298.4A CN110684015A (zh) 2018-07-06 2018-07-06 靶向alk的protac及其应用

Publications (1)

Publication Number Publication Date
CN110684015A true CN110684015A (zh) 2020-01-14

Family

ID=69107309

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810738298.4A Pending CN110684015A (zh) 2018-07-06 2018-07-06 靶向alk的protac及其应用

Country Status (1)

Country Link
CN (1) CN110684015A (zh)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021036922A1 (zh) * 2019-08-23 2021-03-04 北京泰德制药股份有限公司 抑制并诱导降解egfr和alk的化合物
CN113387931A (zh) * 2020-03-13 2021-09-14 四川海思科制药有限公司 一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
CN113527263A (zh) * 2021-07-20 2021-10-22 南开大学 一种蛋白水解靶向嵌合体及其药物组合物和应用
CN113735824A (zh) * 2021-09-07 2021-12-03 中国科学院成都生物研究所 靶向降解酪氨酸酶的protac及其应用
WO2022012622A1 (en) * 2020-07-16 2022-01-20 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
WO2022028372A1 (zh) * 2020-08-03 2022-02-10 沈阳药科大学 靶向降解黏着斑激酶的化合物及其应用
KR20220035014A (ko) * 2020-09-11 2022-03-21 제이투에이치바이오텍 (주) Egfr 돌연변이 암의 억제용 화합물 및 이들의 의약 용도
WO2022171123A1 (en) * 2021-02-10 2022-08-18 Beigene, Ltd. Egfr degraders and methods of use
WO2022194269A1 (zh) * 2021-03-19 2022-09-22 上海齐鲁制药研究中心有限公司 新型egfr降解剂
CN115109047A (zh) * 2021-09-08 2022-09-27 中国科学院化学研究所 一种基于protac设计的铁死亡诱导剂
WO2022228556A1 (en) * 2021-04-30 2022-11-03 Beigene, Ltd. Egfr degraders and associated methods of use
WO2022242725A1 (zh) * 2021-05-19 2022-11-24 和径医药科技（上海）有限公司 一类新型蛋白降解剂及其应用
CN116102534A (zh) * 2021-11-09 2023-05-12 四川大学 共价PARP PROTACs衍生物及其应用
JP2023520940A (ja) * 2020-04-09 2023-05-22 ユーブラス バイオセラピューティクス インコーポレーテッド 標的プロテアーゼ分解（ｔｅｄ）プラットフォーム
US11912682B2 (en) 2021-01-13 2024-02-27 Monte Rosa Therapeutics, Inc. Isoindolinone compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017204445A2 (ko) * 2016-05-24 2017-11-30 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN109422733A (zh) * 2017-09-03 2019-03-05 上海美志医药科技有限公司 一类抑制并降解酪氨酸蛋白激酶alk的化合物
CN109912655A (zh) * 2017-12-13 2019-06-21 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
CN110357889A (zh) * 2018-04-09 2019-10-22 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017204445A2 (ko) * 2016-05-24 2017-11-30 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN109422733A (zh) * 2017-09-03 2019-03-05 上海美志医药科技有限公司 一类抑制并降解酪氨酸蛋白激酶alk的化合物
CN109912655A (zh) * 2017-12-13 2019-06-21 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
CN110357889A (zh) * 2018-04-09 2019-10-22 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
POWELL, CHELSEA E. EL.AL: "Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
ZHANG, CHENGWEI ET. AL: "Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase(ALK)", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4019021A4 (en) * 2019-08-23 2022-11-02 Beijing Tide Pharmaceutical Co., Ltd. INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK
JP2022546375A (ja) * 2019-08-23 2022-11-04 北京泰徳製薬股▲フン▼有限公司 Ｅｇｆｒおよびａｌｋを阻害してそれらの分解を阻害する化合物
WO2021036922A1 (zh) * 2019-08-23 2021-03-04 北京泰德制药股份有限公司 抑制并诱导降解egfr和alk的化合物
CN113387931A (zh) * 2020-03-13 2021-09-14 四川海思科制药有限公司 一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
JP2023520940A (ja) * 2020-04-09 2023-05-22 ユーブラス バイオセラピューティクス インコーポレーテッド 標的プロテアーゼ分解（ｔｅｄ）プラットフォーム
WO2022012622A1 (en) * 2020-07-16 2022-01-20 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
WO2022028372A1 (zh) * 2020-08-03 2022-02-10 沈阳药科大学 靶向降解黏着斑激酶的化合物及其应用
KR102539755B1 (ko) 2020-09-11 2023-06-05 제이투에이치바이오텍 (주) Egfr 돌연변이 암의 억제용 화합물 및 이들의 의약 용도
KR20220035014A (ko) * 2020-09-11 2022-03-21 제이투에이치바이오텍 (주) Egfr 돌연변이 암의 억제용 화합물 및 이들의 의약 용도
US11912682B2 (en) 2021-01-13 2024-02-27 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
WO2022171123A1 (en) * 2021-02-10 2022-08-18 Beigene, Ltd. Egfr degraders and methods of use
WO2022194269A1 (zh) * 2021-03-19 2022-09-22 上海齐鲁制药研究中心有限公司 新型egfr降解剂
CN116888108B (zh) * 2021-03-19 2024-04-19 上海齐鲁制药研究中心有限公司 新型egfr降解剂
CN116888108A (zh) * 2021-03-19 2023-10-13 上海齐鲁制药研究中心有限公司 新型egfr降解剂
WO2022228556A1 (en) * 2021-04-30 2022-11-03 Beigene, Ltd. Egfr degraders and associated methods of use
WO2022242725A1 (zh) * 2021-05-19 2022-11-24 和径医药科技（上海）有限公司 一类新型蛋白降解剂及其应用
CN113527263A (zh) * 2021-07-20 2021-10-22 南开大学 一种蛋白水解靶向嵌合体及其药物组合物和应用
WO2023035927A1 (zh) * 2021-09-07 2023-03-16 中国科学院成都生物研究所 靶向降解酪氨酸酶的化合物、药物组合物及合成方法和应用
CN113735824A (zh) * 2021-09-07 2021-12-03 中国科学院成都生物研究所 靶向降解酪氨酸酶的protac及其应用
CN115109047B (zh) * 2021-09-08 2024-02-20 中国科学院化学研究所 一种基于protac设计的铁死亡诱导剂
CN115109047A (zh) * 2021-09-08 2022-09-27 中国科学院化学研究所 一种基于protac设计的铁死亡诱导剂
CN116102534A (zh) * 2021-11-09 2023-05-12 四川大学 共价PARP PROTACs衍生物及其应用

Similar Documents

Publication Publication Date Title
CN110684015A (zh) 靶向alk的protac及其应用
WO2021103700A1 (zh) 一种可响应硝基还原酶的乏氧探针化合物及其制备与应用
AU2007341977B2 (en) Targeting of EWS-FLI1 as anti-tumor therapy
CN105418643B (zh) 一种双边生物素‑酞菁锌轭合物及其制备和应用
CN108368086A (zh) 可用于治疗自身免疫疾病的二吡唑基衍生物
CN107056618B (zh) 一种检测硝基还原酶的荧光探针
JP5889987B2 (ja) ポリアミンの新規な蛍光誘導体、その製造方法、および癌性腫瘍の治療における診断手段としてのその使用
CN114276333B (zh) 二氢喹喔啉类溴结构域二价抑制剂
CN110551102B (zh) Alk共价抑制剂及其用途
CN102993275A (zh) 一种博来霉素族衍生物及其抗癌活性
CN112574207B (zh) Erk1/2蛋白激酶抑制剂及其用途
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
CN109705095B (zh) 一种含三氮唑环的稠环对苯醌类cdc25蛋白磷酸酶抑制剂及其制备方法和应用
US20170313885A1 (en) Alkoxysilyl group-containing organic el dye and a method for producing the same
CN114907337B (zh) 靶向cdk4或cdk6的共价抑制剂及其应用
CN112876414B (zh) 一种基于多胺修饰的萘酰亚胺缀合物、其制备方法及应用
CN111925369B (zh) 一类β-咔啉氰基呋喃衍生物及其制备方法与应用
CN111675919B (zh) Pcp及其在制备抗肿瘤药物中的应用
CN114073704A (zh) 具有大环结构的含氟并杂环衍生物的应用
TWI689503B (zh) 以鋅結合劑為基礎的ｅｂｎａ１專一性化合物
CN108164548A (zh) 嘧啶并吗啉衍生物及其制备方法和用途
CN114989068B (zh) 一种可调控电子密度的硫化氢响应荧光探针及其制备工艺与应用
CN114560813B (zh) 一种苯并咪唑类mk2变构抑制剂及其制备方法和应用
CN113087668B (zh) 一类苯并咪唑二聚体、其制备方法及用途
LU500160B1 (en) Novel BH3 Mimetic Peptide Compounds Targeting PTP1B, Preparation Method and Application Thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200114

RJ01 Rejection of invention patent application after publication